Epilepsy

Complex MONDO:0005027 Pathograph 6 Neurological Disease

Ask OpenScientist

Ask a research question about Epilepsy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
0
Inheritance
7
Pathophysiology
0
Histopathology
18
Phenotypes
6
Pathograph
14
Genes
6
Treatments
8
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
12
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
nervous system disorder epilepsy
◆

Subtypes

8
Focal Epilepsy
Seizures originate from a localized brain region.
Generalized Epilepsy
Seizures involve both hemispheres from onset.
Temporal Lobe Epilepsy
Most common focal epilepsy, often with mesial temporal sclerosis.
Juvenile Myoclonic Epilepsy (JME) MONDO:0009696
A rare epilepsy syndrome characterized by adolescence/young adulthood onset of myoclonic with or without other generalized seizure types in an otherwise healthy individual. The EEG shows 3-5.5 Hz generalized spike-waves and polyspike-waves. Photosensitivity is common.
Show evidence (1 reference)
ORPHA:307 SUPPORT
"A rare epilepsy syndrome characterized by adolescence/young adulthood onset of myoclonic with or without other generalized seizure types in an otherwise healthy individual."
Orphanet definition of juvenile myoclonic epilepsy.
Childhood Absence Epilepsy
Frequent brief absence seizures beginning in childhood.
Juvenile Absence Epilepsy (JAE) MONDO:0800453
A genetic epilepsy with onset occurring around puberty, characterized by sporadic occurrence of absence seizures, frequently associated with generalized tonic-clonic seizures and sporadic myoclonic jerks.
Show evidence (1 reference)
ORPHA:1941 SUPPORT
"Juvenile absence epilepsy (JAE) is a genetic epilepsy with onset occurring around puberty."
Orphanet definition of juvenile absence epilepsy.
Epilepsy with Myoclonic-Atonic Seizures (Doose Syndrome) MONDO:0014633
A rare childhood onset epilepsy syndrome characterized by multiple seizure types including myoclonic-atonic seizures that occur usually in previously healthy children.
Show evidence (1 reference)
ORPHA:1942 SUPPORT
"A rare, childhood onset epilepsy syndrome characterized by multiple seizure types including myoclonic-atonic (MA) seizures that occur usually in previously healthy children."
Orphanet definition of epilepsy with myoclonic-atonic seizures.
Self-Limited Neonatal Epilepsy (BFNS) MONDO:0016027
A rare genetic epilepsy syndrome characterized by seizure onset typically in the first week of life, in otherwise healthy newborns, usually resolving within the first year of life. Autosomal dominant inheritance with KCNQ2 and KCNQ3 mutations.
Show evidence (1 reference)
ORPHA:1949 SUPPORT
"A rare genetic epilepsy syndrome characterized by seizures onset typically in the first week of life, in otherwise healthy newborns, and usually resolving within the first year of life."
Orphanet definition of self-limited neonatal epilepsy.
⚙

Pathophysiology

7
Neuronal Hyperexcitability
Imbalance between excitatory (glutamate) and inhibitory (GABA) neurotransmission leads to synchronized, excessive neuronal firing. Ion channel dysfunction is a common mechanism.
Pyramidal Neuron link GABAergic Interneuron link
Synaptic Transmission link
Blood-Brain Barrier Disruption
Loss of tight junction proteins (claudin-5) in brain endothelial cells leads to blood-brain barrier breakdown, allowing albumin extravasation and disruption of ionic homeostasis.
Endothelial Cell link
Blood-Brain Barrier Maintenance link
Downstream
Network Hyperexcitability BBB disruption causes albumin entry and altered ionic balance, increasing neuronal excitability.
Show evidence (3 references)
PMID:35422069 SUPPORT Human Clinical
"claudin-5 protein levels are significantly diminished in surgically resected brain tissue from patients with treatment-resistant epilepsy. Concomitantly, dynamic contrast-enhanced MRI in these patients showed widespread BBB disruption."
Demonstrates that BBB dysfunction occurs in human epilepsy patients and is characterized by loss of tight junction proteins.
PMID:35422069 SUPPORT Model Organism
"inducible knockdown of claudin-5 in mice leads to spontaneous recurrent seizures, severe neuroinflammation, and mortality."
Establishes causal role of BBB dysfunction in seizure generation, showing that disruption of endothelial tight junctions is sufficient to trigger spontaneous seizures.
PMID:35422069 SUPPORT Model Organism
"RepSox, a regulator of claudin-5 expression, can prevent seizure activity in experimental epilepsy."
Provides proof-of-concept that stabilizing the BBB through claudin-5 upregulation can prevent seizures, supporting BBB as a therapeutic target.
Network Hyperexcitability
Abnormal synchronization of neuronal networks that can recruit adjacent or distant brain regions, leading to seizure propagation.
Neuronal Activity link
Neuroinflammation and Gliosis
Activation of microglia and reactive astrocytes following brain injury or during seizures, releasing inflammatory mediators and undergoing morphological changes that alter the brain microenvironment.
Astrocyte link Microglia link
Neuroinflammatory Response link
Downstream
Synaptic Reorganization Inflammatory mediators and glial activation alter synaptic structure and connectivity.
Synaptic Reorganization
Aberrant sprouting, formation of new synaptic connections, and altered synaptic plasticity that promote recurrent excitatory circuits and seizure susceptibility.
Synaptic Plasticity link
mTOR Pathway Hyperactivation
Constitutive activation of the mechanistic target of rapamycin (mTOR) signaling pathway, driving abnormal neuronal growth and development of dysmorphic neurons in focal cortical malformations.
mTOR Signaling link
Downstream
Dysmorphic Neuron Generation Hyperactive mTOR signaling causes abnormal neuronal soma enlargement and cytoskeletal changes.
Show evidence (2 references)
PMID:31174205 SUPPORT Model Organism
"Treatment with the mTORC1 inhibitor rapamycin starting after 3 weeks of age significantly prolonged the survival of Depdc5cc+ mice and partially rescued the behavioral hyperactivity."
Demonstrates that mTORC1 pathway hyperactivation caused by DEPDC5 loss drives epilepsy pathogenesis and that mTOR inhibition can rescue the phenotype.
PMID:31174205 SUPPORT Model Organism
"Rapamycin decreased the enlarged brain size of Depdc5cc+ mice with corresponding decrease in neuronal soma size."
Shows that mTOR hyperactivation causes abnormal neuronal growth contributing to epileptogenesis, which can be reversed by mTOR inhibition.
Dysmorphic Neuron Generation
Formation of abnormally enlarged neurons with cytoskeletal disruption and cellular senescence markers, creating epileptogenic foci in cortical malformations.
Show evidence (2 references)
PMID:38710875 PARTIAL Human Clinical
"We uncovered multiple signatures of cellular senescence in these pathological cells, including p53/p16 expression, SASP expression and senescence-associated β-galactosidase activity."
Supports senescence signatures in pathological cells of mTOR-related FCD, but only partially supports all structural details in this descriptor.
PMID:38710875 PARTIAL Model Organism
"administration of senolytic drugs (dasatinib/quercetin) decreases the load of senescent cells and reduces seizure frequency in an MtorS2215F FCDII preclinical mouse model"
Supports seizure reduction via senolytics in an mTOR-related model, but only partially supports this broader dysmorphic neuron descriptor.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Epilepsy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

18
Nervous System 14
Seizures VERY_FREQUENT Seizure (HP:0001250)
Generalized Tonic-Clonic Seizures VERY_FREQUENT Bilateral tonic-clonic seizure (HP:0002069)
Show evidence (1 reference)
ORPHA:1941 SUPPORT
"HP:0002069 | Bilateral tonic-clonic seizure | Very frequent (99-80%)"
Orphanet phenotype data for juvenile absence epilepsy shows bilateral tonic-clonic seizures are very frequent.
Absence Seizures FREQUENT Generalized non-motor (absence) seizure (HP:0002121)
Show evidence (1 reference)
ORPHA:1941 SUPPORT
"HP:0002121 | Generalized non-motor (absence) seizure | Frequent (79-30%)"
Orphanet data shows absence seizures are frequent in juvenile absence epilepsy.
Focal-Onset Seizures VERY_FREQUENT Focal-onset seizure (HP:0007359)
Show evidence (1 reference)
ORPHA:1949 SUPPORT
"HP:0007359 | Focal-onset seizure | Very frequent (99-80%)"
Orphanet data shows focal-onset seizures are very frequent in self-limited neonatal epilepsy.
Febrile Seizures OCCASIONAL Febrile seizure (within the age range of 3 months to 6 years) (HP:0002373)
Show evidence (1 reference)
ORPHA:307 SUPPORT
"HP:0002373 | Febrile seizure (within the age range of 3 months to 6 years) | Occasional (29-5%)"
Orphanet data shows febrile seizures occur occasionally in JME patients.
EEG Abnormality VERY_FREQUENT EEG abnormality (HP:0002353)
Show evidence (2 references)
ORPHA:307 SUPPORT
"HP:0002392 | EEG with polyspike wave complexes | Very frequent (99-80%)"
Orphanet data shows polyspike-wave complexes on EEG are very frequent in JME.
ORPHA:1949 SUPPORT
"HP:0011188 | Focal EEG discharges with secondary generalization | Very frequent (99-80%)"
Orphanet data shows focal EEG discharges with secondary generalization are very frequent in self-limited neonatal epilepsy.
Postictal Confusion FREQUENT Confusion (HP:0001289)
Confusion following generalized or complex partial seizures
Aura FREQUENT Somatic sensory dysfunction (HP:0003474)
Warning symptoms before focal seizures including visual, somatosensory, olfactory, or psychic phenomena
Memory Impairment Memory impairment (HP:0002354)
Frequently reported in temporal lobe epilepsy; quantitative frequency data across all epilepsy subtypes is limited.
Intellectual Disability FREQUENT Intellectual disability (HP:0001249)
Show evidence (1 reference)
ORPHA:1942 SUPPORT
"HP:0001249 | Intellectual disability | Frequent (79-30%)"
Orphanet data shows intellectual disability is frequent in epilepsy with myoclonic-atonic seizures.
Attention Deficit Hyperactivity Disorder FREQUENT Attention deficit hyperactivity disorder (HP:0007018)
Show evidence (1 reference)
ORPHA:1942 SUPPORT
"HP:0007018 | Attention deficit hyperactivity disorder | Frequent (79-30%)"
Orphanet data shows ADHD is frequent in epilepsy with myoclonic-atonic seizures.
Depression OCCASIONAL Depression (HP:0000716)
Show evidence (3 references)
PMID:23175727 SUPPORT Human Clinical
"overall prevalence of active (current or past-year) depression of 23.1%"
Systematic review and meta-analysis of 14 studies showing 23.1% prevalence of active depression in people with epilepsy.
PMID:23175727 SUPPORT Human Clinical
"overall OR of active depression of 2.77 (95% CI 2.09-3.67) in PWE"
People with epilepsy have 2.77 times higher odds of active depression compared to the general population.
PMID:26549780 SUPPORT Human Clinical
"Several mechanisms explain how epilepsy and comorbidities are associated, including shared risk factors and bidirectional relations."
Keezer et al. reviews the bidirectional relationship between epilepsy and depression, with shared pathophysiological mechanisms.
Anxiety OCCASIONAL Anxiety (HP:0000739)
Show evidence (2 references)
ORPHA:1941 SUPPORT
"HP:0000739 | Anxiety | Occasional (29-5%)"
Orphanet data shows anxiety is an occasional phenotype in juvenile absence epilepsy.
PMID:26549780 SUPPORT Human Clinical
"including depression, anxiety, dementia, migraine, heart disease, peptic ulcers, and arthritis are up to eight times more common in people with epilepsy"
Keezer et al. Lancet Neurol review documents anxiety among the major comorbidities of epilepsy.
Headache Headache (HP:0002315)
Show evidence (1 reference)
PMID:26549780 SUPPORT Human Clinical
"including depression, anxiety, dementia, migraine, heart disease, peptic ulcers, and arthritis are up to eight times more common in people with epilepsy"
Keezer et al. Lancet Neurol review documents migraine as a major comorbidity of epilepsy.
Other 4
Myoclonic Seizures VERY_FREQUENT Myoclonic seizure (HP:0032794)
Show evidence (1 reference)
ORPHA:307 SUPPORT
"HP:0007000 | Morning myoclonic jerks | Very frequent (99-80%)"
Orphanet cites HP:0007000 (Morning myoclonic jerks), a more specific child term of HP:0032794 (Myoclonic seizure). The broader term is used here as it applies across epilepsy subtypes, not just JME.
Myoclonic-Atonic Seizures VERY_FREQUENT Generalized myoclonic-atonic seizure (HP:0011170)
Show evidence (1 reference)
ORPHA:1942 SUPPORT
"HP:0011170 | Myoclonic atonic seizures | Very frequent (99-80%)"
Orphanet data shows myoclonic-atonic seizures are very frequent in Doose syndrome.
Status Epilepticus VERY_RARE Status epilepticus (HP:0002133)
Show evidence (1 reference)
ORPHA:307 SUPPORT
"HP:0002133 | Status epilepticus | Very rare (<4-1%)"
Orphanet data shows status epilepticus is very rare in JME.
Automatisms FREQUENT Focal automatism seizure (HP:0032898)
🧬

Genetic Associations

14
SCN1A (Causative)
Show evidence (3 references)
ORPHA:1942 SUPPORT
"SCN1A | sodium voltage-gated channel alpha subunit 1 | hgnc:10585 | Disease-causing germline mutation(s) in"
Orphanet confirms SCN1A as disease-causing in epilepsy with myoclonic-atonic seizures.
PMID:37812819 SUPPORT Human Clinical
"It is caused by haploinsufficiency of SCN1A gene encoding for the α-subunit of the voltage-gated sodium channel Nav1.1."
Establishes SCN1A haploinsufficiency as the genetic cause of Dravet syndrome epileptic encephalopathy.
PMID:37812819 SUPPORT Model Organism
"Induction of heterozygous Nav1.1 mutation at P30 and P60 elicited susceptibility to the development of both spontaneous and hyperthermia-induced seizures and SUDEP rates comparable to P2-induced mice, with symptom onset accompanied by the characteristic GABAergic interneuron dysfunction."
Demonstrates that SCN1A haploinsufficiency causes seizures through GABAergic interneuron dysfunction, and this mechanism is active throughout life, not just during development.
SCN2A (Causative)
Show evidence (1 reference)
PMID:31205438 SUPPORT
"The voltage-gated sodium channel neuronal type 2 alpha subunit (Navα1.2) encoded by the SCN2A gene causes early infantile epileptic encephalopathy (EIEE) inherited in an autosomal dominant manner."
Establishes SCN2A mutations as a cause of early infantile epileptic encephalopathy.
KCNQ2 (Causative)
Show evidence (2 references)
PMID:17675531 SUPPORT
"Benign familial neonatal seizures are most often caused by mutations in the voltage-gated potassium channel subunit gene KCNQ2. More than 60 mutations have been described in BFNS families, approximately half of which lead to protein truncation."
Establishes KCNQ2 as the most common genetic cause of benign familial neonatal seizures.
ORPHA:1949 SUPPORT
"KCNQ2 | potassium voltage-gated channel subfamily Q member 2 | hgnc:6296 | Disease-causing germline mutation(s) in"
Orphanet confirms KCNQ2 as disease-causing in self-limited neonatal epilepsy.
KCNQ3 (Causative)
Show evidence (2 references)
ORPHA:1949 SUPPORT
"KCNQ3 | potassium voltage-gated channel subfamily Q member 3 | hgnc:6297 | Disease-causing germline mutation(s) in"
Orphanet data shows KCNQ3 as disease-causing in self-limited neonatal epilepsy.
ORPHA:307 SUPPORT
"KCNQ3 | potassium voltage-gated channel subfamily Q member 3 | hgnc:6297 | Major susceptibility factor in"
Orphanet data shows KCNQ3 as a major susceptibility factor in juvenile myoclonic epilepsy.
EFHC1 (Susceptibility)
Show evidence (2 references)
ORPHA:307 SUPPORT
"EFHC1 | EF-hand domain containing 1 | hgnc:16406 | Major susceptibility factor in"
Orphanet data identifies EFHC1 as a major susceptibility factor in JME.
ORPHA:1941 SUPPORT
"EFHC1 | EF-hand domain containing 1 | hgnc:16406 | Major susceptibility factor in"
Orphanet data identifies EFHC1 as a major susceptibility factor in juvenile absence epilepsy.
SLC6A1 (Causative)
Show evidence (1 reference)
ORPHA:1942 SUPPORT
"SLC6A1 | solute carrier family 6 member 1 | hgnc:11042 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet data shows SLC6A1 loss-of-function mutations as disease-causing in epilepsy with myoclonic-atonic seizures.
SYNGAP1 (Causative)
Show evidence (1 reference)
ORPHA:1942 SUPPORT
"SYNGAP1 | synaptic Ras GTPase activating protein 1 | hgnc:11497 | Disease-causing germline mutation(s) in"
Orphanet data shows SYNGAP1 mutations as disease-causing in epilepsy with myoclonic-atonic seizures.
GABRA1 (Susceptibility)
Show evidence (3 references)
PMID:11992121 SUPPORT
"We report that an Ala322Asp mutation in GABRA1, encoding the alpha1 subunit of the gamma-aminobutyric acid receptor subtype A (GABA(A)), is found in affected individuals of a large French Canadian family with juvenile myoclonic epilepsy."
Establishes GABRA1 mutations as a cause of juvenile myoclonic epilepsy through GABA receptor dysfunction.
ORPHA:307 SUPPORT
"GABRA1 | gamma-aminobutyric acid type A receptor subunit alpha1 | hgnc:4075 | Major susceptibility factor in"
Orphanet confirms GABRA1 as a major susceptibility factor in JME.
CGGV:assertion_60478d36-384e-4246-ba8a-730755d6f216-2024-09-03T170000.000Z SUPPORT Other
"GABRA1 | HGNC:4075 | epilepsy | MONDO:0005027 | AD | Definitive"
ClinGen classifies the GABRA1-epilepsy gene-disease relationship as definitive with autosomal dominant inheritance.
CDKL5 (Causative)
Show evidence (1 reference)
PMID:20493745 SUPPORT
"Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been identified in female patients with early onset epileptic encephalopathy and severe mental retardation with a Rett-like phenotype."
Establishes CDKL5 mutations as a cause of early-onset epileptic encephalopathy.
DEPDC5 (Causative)
Show evidence (2 references)
PMID:31174205 SUPPORT Model Organism
"DEPDC5 is now recognized as one of the genes most often implicated in familial/inherited focal epilepsy and brain malformations."
Background statement in a mouse model study establishing DEPDC5 as a major gene in familial focal epilepsy.
PMID:31174205 SUPPORT Model Organism
"Individuals with pathogenic variants in DEPDC5 are at risk for epilepsy, associated neuropsychiatric comorbidities and sudden unexplained death in epilepsy."
Background statement documenting the clinical spectrum of DEPDC5-related epilepsy including SUDEP risk.
GABRD (Pathogenic Variants)
Show evidence (1 reference)
CGGV:assertion_64f743b4-408d-40d6-855b-ef9d67fc172e-2023-07-18T190000.000Z SUPPORT Other
"GABRD | HGNC:4084 | epilepsy | MONDO:0005027 | AD | Limited"
ClinGen classifies the GABRD-epilepsy gene-disease relationship as limited with autosomal dominant inheritance.
GABRG2 (Pathogenic Variants)
Show evidence (1 reference)
CGGV:assertion_3a3176e9-ac0c-41fe-ae40-0750726c33d8-2020-01-21T170000.000Z SUPPORT Other
"GABRG2 | HGNC:4087 | epilepsy | MONDO:0005027 | AD | Definitive"
ClinGen classifies the GABRG2-epilepsy gene-disease relationship as definitive with autosomal dominant inheritance.
KPNA7 (Pathogenic Variants)
Show evidence (1 reference)
CGGV:assertion_9aa05adf-d315-4a06-b4f2-c5a5f6a23700-2025-10-07T160000.000Z SUPPORT Other
"KPNA7 | HGNC:21839 | epilepsy | MONDO:0005027 | AR | Limited"
ClinGen classifies the KPNA7-epilepsy gene-disease relationship as limited with autosomal recessive inheritance.
PRIMA1 (Pathogenic Variants)
Show evidence (1 reference)
CGGV:assertion_2247fe32-492c-4a1b-8e1c-5ee13bae944a-2025-01-07T180000.000Z SUPPORT Other
"PRIMA1 | HGNC:18319 | epilepsy | MONDO:0005027 | AR | Limited"
ClinGen classifies the PRIMA1-epilepsy gene-disease relationship as limited with autosomal recessive inheritance.
💊

Treatments

6
Antiseizure Medications
First-line treatment - levetiracetam, lamotrigine, valproate, carbamazepine.
Show evidence (1 reference)
PMID:30587993 SUPPORT
"Meta-analysis of the included RCTs indicated that LEV was as effective as carbamazepine (CBZ; treatment for 6 months: 58.9% vs 64.8%, OR=0.76, 95% CI: 0.50-1.16; 12 months: 54.9% vs 55.5%, OR=1.24, 95% CI: 0.79-1.93), oxcarbazepine (57.7% vs 59.8%, OR=1.34, 95% CI: 0.34-5.23), phenobarbital..."
Meta-analysis demonstrates comparable efficacy of levetiracetam with other first-line antiseizure medications.
Ketogenic Diet
High-fat, low-carbohydrate diet effective for drug-resistant epilepsy.
Show evidence (1 reference)
PMID:18456557 SUPPORT
"28 children (38%) in the diet group had greater than 50% seizure reduction compared with four (6%) controls (p<0.0001), and five children (7%) in the diet group had greater than 90% seizure reduction compared with no controls"
Landmark RCT demonstrating significant seizure reduction with ketogenic diet in drug-resistant childhood epilepsy.
Vagus Nerve Stimulation
Implanted device for drug-resistant epilepsy.
Show evidence (1 reference)
PMID:21838505 SUPPORT
"After VNS, seizure frequency was reduced by an average of 45%, with a 36% reduction in seizures at 3-12 months after surgery and a 51% reduction after > 1 year of therapy."
Meta-analysis of 74 studies with 3321 patients demonstrates VNS efficacy in medically refractory epilepsy.
Epilepsy Surgery
Resection of seizure focus for drug-resistant focal epilepsy.
Show evidence (1 reference)
PMID:11484687 SUPPORT
"At one year, the cumulative proportion of patients who were free of seizures impairing awareness was 58 percent in the surgical group and 8 percent in the medical group (P<0.001)."
Landmark RCT in NEJM demonstrating surgery is superior to prolonged medical therapy for temporal-lobe epilepsy.
Responsive Neurostimulation
Closed-loop brain stimulation for focal epilepsy.
Show evidence (1 reference)
PMID:32690786 SUPPORT
"At 9 years, the median percent reduction in seizure frequency was 75% (p < 0.0001, Wilcoxon signed rank), responder rate was 73%, and 35% had a ≥90% reduction in seizure frequency."
Nine-year prospective study demonstrates sustained efficacy and safety of brain-responsive neurostimulation.
Deep Brain Stimulation
Anterior thalamic stimulation for drug-resistant epilepsy.
Show evidence (1 reference)
PMID:25663221 SUPPORT
"The median percent seizure reduction from baseline at 1 year was 41%, and 69% at 5 years. The responder rate (≥50% reduction in seizure frequency) at 1 year was 43%, and 68% at 5 years."
SANTE trial 5-year follow-up demonstrates sustained efficacy of anterior thalamic deep brain stimulation.
🌍

Environmental Factors

5
Traumatic Brain Injury
Major cause of acquired epilepsy
CNS Infections
Meningitis, encephalitis
Stroke
Leading cause in older adults
Brain Tumors
Can cause focal epilepsy
Perinatal Injury
Hypoxic-ischemic encephalopathy
{ }

Source YAML

click to show 
name: Epilepsy
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-05-01T12:00:00Z'
category: Complex
parents:
- Neurological Disease
disease_term:
  preferred_term: epilepsy
  term:
    id: MONDO:0005027
    label: epilepsy
prevalence:
- population: Global
  percentage: 6.38 per 1,000 (active epilepsy)
  evidence:
  - reference: PMID:27986877
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The point prevalence of active epilepsy was 6.38 per 1,000 persons"
    explanation: Systematic review and meta-analysis of 222 studies providing the most comprehensive global prevalence estimate for active epilepsy.
- population: Drug-Resistant Epilepsy
  percentage: 30% of epilepsy patients
  evidence:
  - reference: PMID:30426482
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pooled prevalence proportion of DRE among epilepsy patients was 0.30"
    explanation: Meta-analysis of 35 studies showing approximately 30% of epilepsy patients develop drug resistance.
- population: Juvenile Myoclonic Epilepsy (Norway)
  percentage: 5.6 per 10,000
  evidence:
  - reference: PMID:27861775
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The point prevalence was estimated at 5.6/10,000. JME constituted 9.3% of all epilepsies in the age group we investigated."
    explanation: Population-based study providing JME-specific prevalence in Norway.
has_subtypes:
- name: Focal Epilepsy
  description: Seizures originate from a localized brain region.
- name: Generalized Epilepsy
  description: Seizures involve both hemispheres from onset.
- name: Temporal Lobe Epilepsy
  description: Most common focal epilepsy, often with mesial temporal sclerosis.
- name: Juvenile Myoclonic Epilepsy
  display_name: Juvenile Myoclonic Epilepsy (JME)
  subtype_term:
    preferred_term: juvenile myoclonic epilepsy
    term:
      id: MONDO:0009696
      label: juvenile myoclonic epilepsy
  description: >
    A rare epilepsy syndrome characterized by adolescence/young adulthood onset of myoclonic
    with or without other generalized seizure types in an otherwise healthy individual.
    The EEG shows 3-5.5 Hz generalized spike-waves and polyspike-waves. Photosensitivity is common.
  evidence:
  - reference: ORPHA:307
    supports: SUPPORT
    snippet: "A rare epilepsy syndrome characterized by adolescence/young adulthood onset of myoclonic with or without other generalized seizure types in an otherwise healthy individual."
    explanation: Orphanet definition of juvenile myoclonic epilepsy.
- name: Childhood Absence Epilepsy
  description: Frequent brief absence seizures beginning in childhood.
- name: Juvenile Absence Epilepsy
  display_name: Juvenile Absence Epilepsy (JAE)
  subtype_term:
    preferred_term: juvenile absence epilepsy
    term:
      id: MONDO:0800453
      label: juvenile absence epilepsy
  description: >
    A genetic epilepsy with onset occurring around puberty, characterized by sporadic
    occurrence of absence seizures, frequently associated with generalized tonic-clonic
    seizures and sporadic myoclonic jerks.
  evidence:
  - reference: ORPHA:1941
    supports: SUPPORT
    snippet: "Juvenile absence epilepsy (JAE) is a genetic epilepsy with onset occurring around puberty."
    explanation: Orphanet definition of juvenile absence epilepsy.
- name: Epilepsy with Myoclonic-Atonic Seizures
  display_name: Epilepsy with Myoclonic-Atonic Seizures (Doose Syndrome)
  subtype_term:
    preferred_term: epilepsy with myoclonic atonic seizures
    term:
      id: MONDO:0014633
      label: epilepsy with myoclonic atonic seizures
  description: >
    A rare childhood onset epilepsy syndrome characterized by multiple seizure types
    including myoclonic-atonic seizures that occur usually in previously healthy children.
  evidence:
  - reference: ORPHA:1942
    supports: SUPPORT
    snippet: "A rare, childhood onset epilepsy syndrome characterized by multiple seizure types including myoclonic-atonic (MA) seizures that occur usually in previously healthy children."
    explanation: Orphanet definition of epilepsy with myoclonic-atonic seizures.
- name: Self-Limited Neonatal Epilepsy
  display_name: Self-Limited Neonatal Epilepsy (BFNS)
  subtype_term:
    preferred_term: self-limited neonatal epilepsy
    term:
      id: MONDO:0016027
      label: benign neonatal seizures
  description: >
    A rare genetic epilepsy syndrome characterized by seizure onset typically in the first
    week of life, in otherwise healthy newborns, usually resolving within the first year of life.
    Autosomal dominant inheritance with KCNQ2 and KCNQ3 mutations.
  evidence:
  - reference: ORPHA:1949
    supports: SUPPORT
    snippet: "A rare genetic epilepsy syndrome characterized by seizures onset typically in the first week of life, in otherwise healthy newborns, and usually resolving within the first year of life."
    explanation: Orphanet definition of self-limited neonatal epilepsy.
pathophysiology:
- name: Neuronal Hyperexcitability
  description: >
    Imbalance between excitatory (glutamate) and inhibitory (GABA)
    neurotransmission leads to synchronized, excessive neuronal firing.
    Ion channel dysfunction is a common mechanism.
  cell_types:
  - preferred_term: Pyramidal Neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  - preferred_term: GABAergic Interneuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: Synaptic Transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
- name: Blood-Brain Barrier Disruption
  description: >
    Loss of tight junction proteins (claudin-5) in brain endothelial cells
    leads to blood-brain barrier breakdown, allowing albumin extravasation
    and disruption of ionic homeostasis.
  cell_types:
  - preferred_term: Endothelial Cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Blood-Brain Barrier Maintenance
    term:
      id: GO:0035633
      label: maintenance of blood-brain barrier
  downstream:
  - target: Network Hyperexcitability
    description: BBB disruption causes albumin entry and altered ionic balance, increasing neuronal excitability.
  evidence:
  - reference: PMID:35422069
    reference_title: "Microvascular stabilization via blood-brain barrier regulation prevents seizure activity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "claudin-5 protein levels are significantly diminished in surgically resected brain tissue from patients with treatment-resistant epilepsy. Concomitantly, dynamic contrast-enhanced MRI in these patients showed widespread BBB disruption."
    explanation: Demonstrates that BBB dysfunction occurs in human epilepsy patients and is characterized by loss of tight junction proteins.
  - reference: PMID:35422069
    reference_title: "Microvascular stabilization via blood-brain barrier regulation prevents seizure activity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "inducible knockdown of claudin-5 in mice leads to spontaneous recurrent seizures, severe neuroinflammation, and mortality."
    explanation: Establishes causal role of BBB dysfunction in seizure generation, showing that disruption of endothelial tight junctions is sufficient to trigger spontaneous seizures.
  - reference: PMID:35422069
    reference_title: "Microvascular stabilization via blood-brain barrier regulation prevents seizure activity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "RepSox, a regulator of claudin-5 expression, can prevent seizure activity in experimental epilepsy."
    explanation: Provides proof-of-concept that stabilizing the BBB through claudin-5 upregulation can prevent seizures, supporting BBB as a therapeutic target.
- name: Network Hyperexcitability
  description: >
    Abnormal synchronization of neuronal networks that can recruit
    adjacent or distant brain regions, leading to seizure propagation.
  biological_processes:
  - preferred_term: Neuronal Activity
    term:
      id: GO:0019226
      label: transmission of nerve impulse
- name: Neuroinflammation and Gliosis
  description: >
    Activation of microglia and reactive astrocytes following brain injury
    or during seizures, releasing inflammatory mediators and undergoing
    morphological changes that alter the brain microenvironment.
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: Neuroinflammatory Response
    term:
      id: GO:0150076
      label: neuroinflammatory response
  downstream:
  - target: Synaptic Reorganization
    description: Inflammatory mediators and glial activation alter synaptic structure and connectivity.
- name: Synaptic Reorganization
  description: >
    Aberrant sprouting, formation of new synaptic connections, and
    altered synaptic plasticity that promote recurrent excitatory circuits
    and seizure susceptibility.
  biological_processes:
  - preferred_term: Synaptic Plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
- name: mTOR Pathway Hyperactivation
  description: >
    Constitutive activation of the mechanistic target of rapamycin (mTOR)
    signaling pathway, driving abnormal neuronal growth and development
    of dysmorphic neurons in focal cortical malformations.
  biological_processes:
  - preferred_term: mTOR Signaling
    term:
      id: GO:0031929
      label: TOR signaling
  downstream:
  - target: Dysmorphic Neuron Generation
    description: Hyperactive mTOR signaling causes abnormal neuronal soma enlargement and cytoskeletal changes.
  evidence:
  - reference: PMID:31174205
    reference_title: "Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Treatment with the mTORC1 inhibitor rapamycin starting after 3 weeks of age significantly prolonged the survival of Depdc5cc+ mice and partially rescued the behavioral hyperactivity."
    explanation: Demonstrates that mTORC1 pathway hyperactivation caused by DEPDC5 loss drives epilepsy pathogenesis and that mTOR inhibition can rescue the phenotype.
  - reference: PMID:31174205
    reference_title: "Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Rapamycin decreased the enlarged brain size of Depdc5cc+ mice with corresponding decrease in neuronal soma size."
    explanation: Shows that mTOR hyperactivation causes abnormal neuronal growth contributing to epileptogenesis, which can be reversed by mTOR inhibition.
- name: Dysmorphic Neuron Generation
  description: >
    Formation of abnormally enlarged neurons with cytoskeletal disruption
    and cellular senescence markers, creating epileptogenic foci in
    cortical malformations.
  evidence:
  - reference: PMID:38710875
    reference_title: "Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "We uncovered multiple signatures of cellular senescence in these pathological cells, including p53/p16 expression, SASP expression and senescence-associated β-galactosidase activity."
    explanation: Supports senescence signatures in pathological cells of mTOR-related FCD, but only partially supports all structural details in this descriptor.
  - reference: PMID:38710875
    reference_title: "Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "administration of senolytic drugs (dasatinib/quercetin) decreases the load of senescent cells and reduces seizure frequency in an MtorS2215F FCDII preclinical mouse model"
    explanation: Supports seizure reduction via senolytics in an mTOR-related model, but only partially supports this broader dysmorphic neuron descriptor.
phenotypes:
- name: Seizures
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
- name: Generalized Tonic-Clonic Seizures
  category: Neurological
  frequency: VERY_FREQUENT
  subtype: Juvenile Absence Epilepsy
  description: >
    Bilateral tonic stiffening followed by rhythmic clonic jerking, with loss
    of consciousness. The most common seizure type across multiple epilepsy syndromes.
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  evidence:
  - reference: ORPHA:1941
    supports: SUPPORT
    snippet: "HP:0002069 | Bilateral tonic-clonic seizure | Very frequent (99-80%)"
    explanation: Orphanet phenotype data for juvenile absence epilepsy shows bilateral tonic-clonic seizures are very frequent.
- name: Absence Seizures
  category: Neurological
  frequency: FREQUENT
  subtype: Juvenile Absence Epilepsy
  description: >
    Brief episodes of impaired awareness with behavioral arrest, typically lasting
    5-30 seconds with abrupt onset and offset. Characteristic 3 Hz spike-and-wave
    discharges on EEG.
  phenotype_term:
    preferred_term: Absence seizure
    term:
      id: HP:0002121
      label: Generalized non-motor (absence) seizure
  evidence:
  - reference: ORPHA:1941
    supports: SUPPORT
    snippet: "HP:0002121 | Generalized non-motor (absence) seizure | Frequent (79-30%)"
    explanation: Orphanet data shows absence seizures are frequent in juvenile absence epilepsy.
- name: Myoclonic Seizures
  category: Neurological
  frequency: VERY_FREQUENT
  subtype: Juvenile Myoclonic Epilepsy
  description: >
    Brief, shock-like involuntary jerks of a muscle or group of muscles,
    often occurring in the morning shortly after awakening.
  phenotype_term:
    preferred_term: Myoclonic seizure
    term:
      id: HP:0032794
      label: Myoclonic seizure
  evidence:
  - reference: ORPHA:307
    supports: SUPPORT
    snippet: "HP:0007000 | Morning myoclonic jerks | Very frequent (99-80%)"
    explanation: Orphanet cites HP:0007000 (Morning myoclonic jerks), a more specific child term of HP:0032794 (Myoclonic seizure). The broader term is used here as it applies across epilepsy subtypes, not just JME.
- name: Focal-Onset Seizures
  category: Neurological
  frequency: VERY_FREQUENT
  subtype: Self-Limited Neonatal Epilepsy
  description: >
    Seizures originating from a specific brain region, with clinical features
    reflecting the function of the cortical area involved. May be with preserved
    or impaired awareness.
  phenotype_term:
    preferred_term: Focal-onset seizure
    term:
      id: HP:0007359
      label: Focal-onset seizure
  evidence:
  - reference: ORPHA:1949
    supports: SUPPORT
    snippet: "HP:0007359 | Focal-onset seizure | Very frequent (99-80%)"
    explanation: Orphanet data shows focal-onset seizures are very frequent in self-limited neonatal epilepsy.
- name: Myoclonic-Atonic Seizures
  category: Neurological
  frequency: VERY_FREQUENT
  subtype: Epilepsy with Myoclonic-Atonic Seizures
  description: >
    Seizures with a brief myoclonic jerk followed by loss of muscle tone causing
    a fall. The defining seizure type in Doose syndrome.
  phenotype_term:
    preferred_term: Myoclonic-atonic seizure
    term:
      id: HP:0011170
      label: Generalized myoclonic-atonic seizure
  evidence:
  - reference: ORPHA:1942
    supports: SUPPORT
    snippet: "HP:0011170 | Myoclonic atonic seizures | Very frequent (99-80%)"
    explanation: Orphanet data shows myoclonic-atonic seizures are very frequent in Doose syndrome.
- name: Status Epilepticus
  category: Neurological
  frequency: VERY_RARE
  subtype: Juvenile Myoclonic Epilepsy
  description: >
    Prolonged seizure activity (>5 minutes) or recurrent seizures without recovery
    of consciousness between episodes. A medical emergency with significant mortality risk.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: ORPHA:307
    supports: SUPPORT
    snippet: "HP:0002133 | Status epilepticus | Very rare (<4-1%)"
    explanation: Orphanet data shows status epilepticus is very rare in JME.
- name: Febrile Seizures
  category: Neurological
  frequency: OCCASIONAL
  description: >
    Seizures occurring in the setting of fever in children aged 3 months to 6 years.
    A risk factor for later development of epilepsy.
  phenotype_term:
    preferred_term: Febrile seizure
    term:
      id: HP:0002373
      label: Febrile seizure (within the age range of 3 months to 6 years)
  evidence:
  - reference: ORPHA:307
    supports: SUPPORT
    snippet: "HP:0002373 | Febrile seizure (within the age range of 3 months to 6 years) | Occasional (29-5%)"
    explanation: Orphanet data shows febrile seizures occur occasionally in JME patients.
- name: EEG Abnormality
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >
    Abnormal electroencephalographic patterns including interictal epileptiform
    discharges, spike-and-wave complexes, and polyspike-wave complexes. EEG is
    a cornerstone of epilepsy diagnosis and classification.
  phenotype_term:
    preferred_term: EEG abnormality
    term:
      id: HP:0002353
      label: EEG abnormality
  evidence:
  - reference: ORPHA:307
    supports: SUPPORT
    snippet: "HP:0002392 | EEG with polyspike wave complexes | Very frequent (99-80%)"
    explanation: Orphanet data shows polyspike-wave complexes on EEG are very frequent in JME.
  - reference: ORPHA:1949
    supports: SUPPORT
    snippet: "HP:0011188 | Focal EEG discharges with secondary generalization | Very frequent (99-80%)"
    explanation: Orphanet data shows focal EEG discharges with secondary generalization are very frequent in self-limited neonatal epilepsy.
- name: Postictal Confusion
  category: Neurological
  frequency: FREQUENT
  notes: Confusion following generalized or complex partial seizures
  phenotype_term:
    preferred_term: Confusion
    term:
      id: HP:0001289
      label: Confusion
- name: Aura
  category: Neurological
  frequency: FREQUENT
  subtype: Focal Epilepsy
  notes: Warning symptoms before focal seizures including visual, somatosensory, olfactory, or psychic phenomena
  phenotype_term:
    preferred_term: Sensory Disturbance
    term:
      id: HP:0003474
      label: Somatic sensory dysfunction
- name: Automatisms
  category: Neurological
  frequency: FREQUENT
  subtype: Temporal Lobe Epilepsy
  description: >
    Repetitive, semi-purposeful motor activities occurring during focal seizures
    with impaired awareness. Common in temporal lobe epilepsy, including orofacial
    and manual automatisms.
  phenotype_term:
    preferred_term: Focal automatism seizure
    term:
      id: HP:0032898
      label: Focal automatism seizure
- name: Memory Impairment
  category: Cognitive
  description: >
    Cognitive dysfunction affecting memory is common, particularly in temporal
    lobe epilepsy. Both seizures and some antiseizure medications contribute.
  notes: Frequently reported in temporal lobe epilepsy; quantitative frequency data across all epilepsy subtypes is limited.
  phenotype_term:
    preferred_term: Memory Impairment
    term:
      id: HP:0002354
      label: Memory impairment
- name: Intellectual Disability
  category: Cognitive
  frequency: FREQUENT
  subtype: Epilepsy with Myoclonic-Atonic Seizures
  description: >
    Intellectual disability is associated with several epilepsy syndromes,
    particularly the epileptic encephalopathies and myoclonic-atonic epilepsy.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:1942
    supports: SUPPORT
    snippet: "HP:0001249 | Intellectual disability | Frequent (79-30%)"
    explanation: Orphanet data shows intellectual disability is frequent in epilepsy with myoclonic-atonic seizures.
- name: Attention Deficit Hyperactivity Disorder
  category: Psychiatric
  frequency: FREQUENT
  subtype: Epilepsy with Myoclonic-Atonic Seizures
  description: >
    ADHD is a common comorbidity across epilepsy syndromes, particularly
    in childhood-onset forms.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: ORPHA:1942
    supports: SUPPORT
    snippet: "HP:0007018 | Attention deficit hyperactivity disorder | Frequent (79-30%)"
    explanation: Orphanet data shows ADHD is frequent in epilepsy with myoclonic-atonic seizures.
- name: Depression
  category: Psychiatric
  frequency: OCCASIONAL
  description: >
    Depression is highly prevalent in people with epilepsy, with a bidirectional
    relationship. Both shared neurobiological mechanisms and psychosocial factors
    contribute.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:23175727
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "overall prevalence of active (current or past-year) depression of 23.1%"
    explanation: Systematic review and meta-analysis of 14 studies showing 23.1% prevalence of active depression in people with epilepsy.
  - reference: PMID:23175727
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "overall OR of active depression of 2.77 (95% CI 2.09-3.67) in PWE"
    explanation: People with epilepsy have 2.77 times higher odds of active depression compared to the general population.
  - reference: PMID:26549780
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several mechanisms explain how epilepsy and comorbidities are associated, including shared risk factors and bidirectional relations."
    explanation: Keezer et al. reviews the bidirectional relationship between epilepsy and depression, with shared pathophysiological mechanisms.
- name: Anxiety
  category: Psychiatric
  frequency: OCCASIONAL
  subtype: Juvenile Absence Epilepsy
  description: >
    Anxiety disorders are common in epilepsy, with both interictal and
    peri-ictal anxiety. Prevalence is significantly elevated compared to
    the general population.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: ORPHA:1941
    supports: SUPPORT
    snippet: "HP:0000739 | Anxiety | Occasional (29-5%)"
    explanation: Orphanet data shows anxiety is an occasional phenotype in juvenile absence epilepsy.
  - reference: PMID:26549780
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including depression, anxiety, dementia, migraine, heart disease, peptic ulcers, and arthritis are up to eight times more common in people with epilepsy"
    explanation: Keezer et al. Lancet Neurol review documents anxiety among the major comorbidities of epilepsy.
- name: Headache
  category: Neurological
  description: >
    Migraine and other headache disorders are common comorbidities of epilepsy,
    with a bidirectional relationship. Both peri-ictal headaches and interictal
    migraine occur.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:26549780
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including depression, anxiety, dementia, migraine, heart disease, peptic ulcers, and arthritis are up to eight times more common in people with epilepsy"
    explanation: Keezer et al. Lancet Neurol review documents migraine as a major comorbidity of epilepsy.
progression:
- phase: SUDEP Risk
  notes: >
    Sudden unexpected death in epilepsy (SUDEP) can affect individuals of any age
    but is most common in younger adults (aged 20-45 years). Generalized tonic-clonic
    seizures are the greatest risk factor. Postictal apnea and bradycardia progress
    to asystole.
  evidence:
  - reference: PMID:27571159
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sudden unexpected death in epilepsy (SUDEP) can affect individuals of any age, but is most common in younger adults (aged 20-45 years)."
    explanation: Devinsky et al. Lancet Neurol review establishes SUDEP epidemiology and age distribution.
  - reference: PMID:27571159
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Generalised tonic-clonic seizures are the greatest risk factor for SUDEP"
    explanation: Identifies the primary risk factor for SUDEP.
  - reference: PMID:27571159
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Typically, postictal apnoea and bradycardia progress to asystole and death."
    explanation: Describes the pathophysiological mechanism of SUDEP.
genetic:
- name: SCN1A
  association: Causative
  notes: Dravet syndrome, GEFS+; also disease-causing in epilepsy with myoclonic-atonic seizures
  evidence:
  - reference: ORPHA:1942
    supports: SUPPORT
    snippet: "SCN1A | sodium voltage-gated channel alpha subunit 1 | hgnc:10585 | Disease-causing germline mutation(s) in"
    explanation: Orphanet confirms SCN1A as disease-causing in epilepsy with myoclonic-atonic seizures.
  - reference: PMID:37812819
    reference_title: "Temporal manipulation of the Scn1a gene reveals its essential role in adult brain function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is caused by haploinsufficiency of SCN1A gene encoding for the α-subunit of the voltage-gated sodium channel Nav1.1."
    explanation: Establishes SCN1A haploinsufficiency as the genetic cause of Dravet syndrome epileptic encephalopathy.
  - reference: PMID:37812819
    reference_title: "Temporal manipulation of the Scn1a gene reveals its essential role in adult brain function."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Induction of heterozygous Nav1.1 mutation at P30 and P60 elicited susceptibility to the development of both spontaneous and hyperthermia-induced seizures and SUDEP rates comparable to P2-induced mice, with symptom onset accompanied by the characteristic GABAergic interneuron dysfunction."
    explanation: Demonstrates that SCN1A haploinsufficiency causes seizures through GABAergic interneuron dysfunction, and this mechanism is active throughout life, not just during development.
- name: SCN2A
  association: Causative
  notes: Early infantile epileptic encephalopathy
  evidence:
  - reference: PMID:31205438
    reference_title: "Biallelic SCN2A Gene Mutation Causing Early Infantile Epileptic Encephalopathy: Case Report and Review."
    supports: SUPPORT
    snippet: "The voltage-gated sodium channel neuronal type 2 alpha subunit (Navα1.2) encoded by the SCN2A gene causes early infantile epileptic encephalopathy (EIEE) inherited in an autosomal dominant manner."
    explanation: Establishes SCN2A mutations as a cause of early infantile epileptic encephalopathy.
- name: KCNQ2
  association: Causative
  notes: Benign familial neonatal seizures (self-limited neonatal epilepsy)
  evidence:
  - reference: PMID:17675531
    reference_title: "Deletions or duplications in KCNQ2 can cause benign familial neonatal seizures."
    supports: SUPPORT
    snippet: "Benign familial neonatal seizures are most often caused by mutations in the voltage-gated potassium channel subunit gene KCNQ2. More than 60 mutations have been described in BFNS families, approximately half of which lead to protein truncation."
    explanation: Establishes KCNQ2 as the most common genetic cause of benign familial neonatal seizures.
  - reference: ORPHA:1949
    supports: SUPPORT
    snippet: "KCNQ2 | potassium voltage-gated channel subfamily Q member 2 | hgnc:6296 | Disease-causing germline mutation(s) in"
    explanation: Orphanet confirms KCNQ2 as disease-causing in self-limited neonatal epilepsy.
- name: KCNQ3
  association: Causative
  notes: Self-limited neonatal epilepsy; major susceptibility factor in JME
  evidence:
  - reference: ORPHA:1949
    supports: SUPPORT
    snippet: "KCNQ3 | potassium voltage-gated channel subfamily Q member 3 | hgnc:6297 | Disease-causing germline mutation(s) in"
    explanation: Orphanet data shows KCNQ3 as disease-causing in self-limited neonatal epilepsy.
  - reference: ORPHA:307
    supports: SUPPORT
    snippet: "KCNQ3 | potassium voltage-gated channel subfamily Q member 3 | hgnc:6297 | Major susceptibility factor in"
    explanation: Orphanet data shows KCNQ3 as a major susceptibility factor in juvenile myoclonic epilepsy.
- name: EFHC1
  association: Susceptibility
  notes: Major susceptibility factor in JME and juvenile absence epilepsy
  evidence:
  - reference: ORPHA:307
    supports: SUPPORT
    snippet: "EFHC1 | EF-hand domain containing 1 | hgnc:16406 | Major susceptibility factor in"
    explanation: Orphanet data identifies EFHC1 as a major susceptibility factor in JME.
  - reference: ORPHA:1941
    supports: SUPPORT
    snippet: "EFHC1 | EF-hand domain containing 1 | hgnc:16406 | Major susceptibility factor in"
    explanation: Orphanet data identifies EFHC1 as a major susceptibility factor in juvenile absence epilepsy.
- name: SLC6A1
  association: Causative
  notes: Epilepsy with myoclonic-atonic seizures (loss of function mutations)
  evidence:
  - reference: ORPHA:1942
    supports: SUPPORT
    snippet: "SLC6A1 | solute carrier family 6 member 1 | hgnc:11042 | Disease-causing germline mutation(s) (loss of function) in"
    explanation: Orphanet data shows SLC6A1 loss-of-function mutations as disease-causing in epilepsy with myoclonic-atonic seizures.
- name: SYNGAP1
  association: Causative
  notes: Epilepsy with myoclonic-atonic seizures
  evidence:
  - reference: ORPHA:1942
    supports: SUPPORT
    snippet: "SYNGAP1 | synaptic Ras GTPase activating protein 1 | hgnc:11497 | Disease-causing germline mutation(s) in"
    explanation: Orphanet data shows SYNGAP1 mutations as disease-causing in epilepsy with myoclonic-atonic seizures.
- name: GABRA1
  association: Susceptibility
  notes: Major susceptibility factor in juvenile myoclonic epilepsy
  evidence:
  - reference: PMID:11992121
    reference_title: "Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy."
    supports: SUPPORT
    snippet: "We report that an Ala322Asp mutation in GABRA1, encoding the alpha1 subunit of the gamma-aminobutyric acid receptor subtype A (GABA(A)), is found in affected individuals of a large French Canadian family with juvenile myoclonic epilepsy."
    explanation: Establishes GABRA1 mutations as a cause of juvenile myoclonic epilepsy through GABA receptor dysfunction.
  - reference: ORPHA:307
    supports: SUPPORT
    snippet: "GABRA1 | gamma-aminobutyric acid type A receptor subunit alpha1 | hgnc:4075 | Major susceptibility factor in"
    explanation: Orphanet confirms GABRA1 as a major susceptibility factor in JME.
  - reference: CGGV:assertion_60478d36-384e-4246-ba8a-730755d6f216-2024-09-03T170000.000Z
    reference_title: "GABRA1 / epilepsy (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GABRA1 | HGNC:4075 | epilepsy | MONDO:0005027 | AD | Definitive"
    explanation: ClinGen classifies the GABRA1-epilepsy gene-disease relationship as definitive with autosomal dominant inheritance.
- name: CDKL5
  association: Causative
  notes: Early-onset epileptic encephalopathy
  evidence:
  - reference: PMID:20493745
    reference_title: "Epilepsy caused by CDKL5 mutations."
    supports: SUPPORT
    snippet: "Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been identified in female patients with early onset epileptic encephalopathy and severe mental retardation with a Rett-like phenotype."
    explanation: Establishes CDKL5 mutations as a cause of early-onset epileptic encephalopathy.
- name: DEPDC5
  association: Causative
  notes: Familial focal epilepsy, focal cortical dysplasia; mTOR pathway (GATOR1 complex)
  evidence:
  - reference: PMID:31174205
    reference_title: "Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "DEPDC5 is now recognized as one of the genes most often implicated in familial/inherited focal epilepsy and brain malformations."
    explanation: Background statement in a mouse model study establishing DEPDC5 as a major gene in familial focal epilepsy.
  - reference: PMID:31174205
    reference_title: "Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Individuals with pathogenic variants in DEPDC5 are at risk for epilepsy, associated neuropsychiatric comorbidities and sudden unexplained death in epilepsy."
    explanation: Background statement documenting the clinical spectrum of DEPDC5-related epilepsy including SUDEP risk.
- name: GABRD
  gene_term:
    preferred_term: GABRD
    term:
      id: hgnc:4084
      label: GABRD
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_64f743b4-408d-40d6-855b-ef9d67fc172e-2023-07-18T190000.000Z
    reference_title: "GABRD / epilepsy (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GABRD | HGNC:4084 | epilepsy | MONDO:0005027 | AD | Limited"
    explanation: ClinGen classifies the GABRD-epilepsy gene-disease relationship as limited with autosomal dominant inheritance.
- name: GABRG2
  gene_term:
    preferred_term: GABRG2
    term:
      id: hgnc:4087
      label: GABRG2
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_3a3176e9-ac0c-41fe-ae40-0750726c33d8-2020-01-21T170000.000Z
    reference_title: "GABRG2 / epilepsy (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GABRG2 | HGNC:4087 | epilepsy | MONDO:0005027 | AD | Definitive"
    explanation: ClinGen classifies the GABRG2-epilepsy gene-disease relationship as definitive with autosomal dominant inheritance.
- name: KPNA7
  gene_term:
    preferred_term: KPNA7
    term:
      id: hgnc:21839
      label: KPNA7
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_9aa05adf-d315-4a06-b4f2-c5a5f6a23700-2025-10-07T160000.000Z
    reference_title: "KPNA7 / epilepsy (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "KPNA7 | HGNC:21839 | epilepsy | MONDO:0005027 | AR | Limited"
    explanation: ClinGen classifies the KPNA7-epilepsy gene-disease relationship as limited with autosomal recessive inheritance.
- name: PRIMA1
  gene_term:
    preferred_term: PRIMA1
    term:
      id: hgnc:18319
      label: PRIMA1
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_2247fe32-492c-4a1b-8e1c-5ee13bae944a-2025-01-07T180000.000Z
    reference_title: "PRIMA1 / epilepsy (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PRIMA1 | HGNC:18319 | epilepsy | MONDO:0005027 | AR | Limited"
    explanation: ClinGen classifies the PRIMA1-epilepsy gene-disease relationship as limited with autosomal recessive inheritance.
environmental:
- name: Traumatic Brain Injury
  notes: Major cause of acquired epilepsy
- name: CNS Infections
  notes: Meningitis, encephalitis
- name: Stroke
  notes: Leading cause in older adults
- name: Brain Tumors
  notes: Can cause focal epilepsy
- name: Perinatal Injury
  notes: Hypoxic-ischemic encephalopathy
treatments:
- name: Antiseizure Medications
  description: First-line treatment - levetiracetam, lamotrigine, valproate, carbamazepine.
  evidence:
  - reference: PMID:30587993
    reference_title: "Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles."
    supports: SUPPORT
    snippet: "Meta-analysis of the included RCTs indicated that LEV was as effective as carbamazepine (CBZ; treatment for 6 months: 58.9% vs 64.8%, OR=0.76, 95% CI: 0.50-1.16; 12 months: 54.9% vs 55.5%, OR=1.24, 95% CI: 0.79-1.93), oxcarbazepine (57.7% vs 59.8%, OR=1.34, 95% CI: 0.34-5.23), phenobarbital (50.0% vs 50.9%, OR=1.20, 95% CI: 0.51-2.82) and lamotrigine (LTG; 61.5% vs 57.7%, OR=1.22, 95% CI: 0.90-1.66)."
    explanation: Meta-analysis demonstrates comparable efficacy of levetiracetam with other first-line antiseizure medications.
- name: Ketogenic Diet
  description: High-fat, low-carbohydrate diet effective for drug-resistant epilepsy.
  evidence:
  - reference: PMID:18456557
    reference_title: "The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial."
    supports: SUPPORT
    snippet: "28 children (38%) in the diet group had greater than 50% seizure reduction compared with four (6%) controls (p<0.0001), and five children (7%) in the diet group had greater than 90% seizure reduction compared with no controls"
    explanation: Landmark RCT demonstrating significant seizure reduction with ketogenic diet in drug-resistant childhood epilepsy.
- name: Vagus Nerve Stimulation
  description: Implanted device for drug-resistant epilepsy.
  evidence:
  - reference: PMID:21838505
    reference_title: "Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response."
    supports: SUPPORT
    snippet: "After VNS, seizure frequency was reduced by an average of 45%, with a 36% reduction in seizures at 3-12 months after surgery and a 51% reduction after > 1 year of therapy."
    explanation: Meta-analysis of 74 studies with 3321 patients demonstrates VNS efficacy in medically refractory epilepsy.
- name: Epilepsy Surgery
  description: Resection of seizure focus for drug-resistant focal epilepsy.
  evidence:
  - reference: PMID:11484687
    reference_title: "A randomized, controlled trial of surgery for temporal-lobe epilepsy."
    supports: SUPPORT
    snippet: "At one year, the cumulative proportion of patients who were free of seizures impairing awareness was 58 percent in the surgical group and 8 percent in the medical group (P<0.001)."
    explanation: Landmark RCT in NEJM demonstrating surgery is superior to prolonged medical therapy for temporal-lobe epilepsy.
- name: Responsive Neurostimulation
  description: Closed-loop brain stimulation for focal epilepsy.
  evidence:
  - reference: PMID:32690786
    reference_title: "Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy."
    supports: SUPPORT
    snippet: "At 9 years, the median percent reduction in seizure frequency was 75% (p < 0.0001, Wilcoxon signed rank), responder rate was 73%, and 35% had a ≥90% reduction in seizure frequency."
    explanation: Nine-year prospective study demonstrates sustained efficacy and safety of brain-responsive neurostimulation.
- name: Deep Brain Stimulation
  description: Anterior thalamic stimulation for drug-resistant epilepsy.
  evidence:
  - reference: PMID:25663221
    reference_title: "Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy."
    supports: SUPPORT
    snippet: "The median percent seizure reduction from baseline at 1 year was 41%, and 69% at 5 years. The responder rate (≥50% reduction in seizure frequency) at 1 year was 43%, and 68% at 5 years."
    explanation: SANTE trial 5-year follow-up demonstrates sustained efficacy of anterior thalamic deep brain stimulation.
classifications:
  harrisons_chapter:
  - classification_value: nervous system disorder
  - classification_value: epilepsy
datasets:
references:
- reference: DOI:10.1002/ctm2.70072
  title: Excitatory neurons and oligodendrocyte precursor cells are vulnerable to focal cortical dysplasia type IIIa as suggested by single‐nucleus multiomics
  findings: []
- reference: DOI:10.1002/hsr2.1896
  title: 'Advances in understanding the pathogenesis of epilepsy: Unraveling the molecular mechanisms'
  findings: []
- reference: DOI:10.1038/s41467-022-29657-y
  title: Microvascular stabilization via blood-brain barrier regulation prevents seizure activity
  findings: []
- reference: DOI:10.1038/s41593-024-01634-2
  title: Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy
  findings: []
- reference: DOI:10.1093/brain/awad349
  title: Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model
  findings: []
- reference: DOI:10.1093/hmg/ddz123
  title: Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice
  findings: []
- reference: DOI:10.3389/fneur.2024.1413023
  title: 'Unveiling the hidden connection: the blood-brain barrier’s role in epilepsy'
  findings: []
- reference: DOI:10.3389/fneur.2024.1466075
  title: Voltage-gated potassium channels and genetic epilepsy
  findings: []
- reference: DOI:10.3389/fneur.2025.1642299
  title: Progress in genetic mechanisms and precise treatment of neurocutaneous syndrome-related epilepsy
  findings: []
- reference: DOI:10.3389/fnins.2025.1634718
  title: 'Dravet syndrome: novel insights into SCN1A-mediated epileptic neurodevelopmental disorders within the molecular diagnostic-therapeutic framework'
  findings: []
- reference: DOI:10.3390/ijms25084161
  title: 'Neuroinflammation and Epilepsy: From Pathophysiology to Therapies Based on Repurposing Drugs'
  findings: []
- reference: DOI:10.7554/elife.91010.3
  title: The mTOR pathway genes MTOR, Rheb, Depdc5, Pten, and Tsc1 have convergent and divergent impacts on cortical neuron development and function
  findings: []
📚

References & Deep Research

References

12
DOI:10.1002/ctm2.70072
Excitatory neurons and oligodendrocyte precursor cells are vulnerable to focal cortical dysplasia type IIIa as suggested by single‐nucleus multiomics
No top-level findings curated for this source.
DOI:10.1002/hsr2.1896
Advances in understanding the pathogenesis of epilepsy: Unraveling the molecular mechanisms
No top-level findings curated for this source.
DOI:10.1038/s41467-022-29657-y
Microvascular stabilization via blood-brain barrier regulation prevents seizure activity
No top-level findings curated for this source.
DOI:10.1038/s41593-024-01634-2
Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy
No top-level findings curated for this source.
DOI:10.1093/brain/awad349
Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model
No top-level findings curated for this source.
DOI:10.1093/hmg/ddz123
Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice
No top-level findings curated for this source.
DOI:10.3389/fneur.2024.1413023
Unveiling the hidden connection: the blood-brain barrier’s role in epilepsy
No top-level findings curated for this source.
DOI:10.3389/fneur.2024.1466075
Voltage-gated potassium channels and genetic epilepsy
No top-level findings curated for this source.
DOI:10.3389/fneur.2025.1642299
Progress in genetic mechanisms and precise treatment of neurocutaneous syndrome-related epilepsy
No top-level findings curated for this source.
DOI:10.3389/fnins.2025.1634718
Dravet syndrome: novel insights into SCN1A-mediated epileptic neurodevelopmental disorders within the molecular diagnostic-therapeutic framework
No top-level findings curated for this source.
DOI:10.3390/ijms25084161
Neuroinflammation and Epilepsy: From Pathophysiology to Therapies Based on Repurposing Drugs
No top-level findings curated for this source.
DOI:10.7554/elife.91010.3
The mTOR pathway genes MTOR, Rheb, Depdc5, Pten, and Tsc1 have convergent and divergent impacts on cortical neuron development and function
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Epilepsy
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 25

Key Pathophysiology Nodes

  • Neuronal Hyperexcitability
  • Blood-Brain Barrier Disruption
  • Network Hyperexcitability
  • Neuroinflammation and Gliosis
  • Synaptic Reorganization
  • mTOR Pathway Hyperactivation
  • Dysmorphic Neuron Generation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1002/ctm2.70072
  • DOI:10.1002/hsr2.1896
  • DOI:10.1038/s41467-022-29657-y
  • DOI:10.1038/s41593-024-01634-2
  • DOI:10.1093/brain/awad349
  • DOI:10.1093/braincomms/fcae231
  • DOI:10.1093/hmg/ddz123
  • DOI:10.3389/fneur.2024.1413023
  • DOI:10.3389/fneur.2024.1466075
  • DOI:10.3389/fneur.2025.1642299
  • DOI:10.3389/fnins.2025.1634718
  • DOI:10.3390/ijms25084161
  • DOI:10.7554/elife.91010.3
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 37 citations 2025-12-17T18:55:38.487872

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Epilepsy
  • MONDO ID: MONDO:0005151
  • Category: Complex

Pathophysiology description (current understanding, 2023–2024 updates)

Epilepsy arises from converging molecular and cellular mechanisms that increase network excitability and synchrony. Core drivers include: (i) excitation–inhibition (E/I) imbalance due to ion channelopathies (e.g., SCN1A, KCNQ2/3, multiple Kv genes) and impaired GABAergic synaptic inhibition; (ii) glial mechanisms of neuroinflammation (microglia, astrocytes), including TLR/NF-κB and inflammasome-related signaling; (iii) blood–brain barrier (BBB) dysfunction with extravasation of serum proteins (e.g., albumin) and downstream TGF-β–astrocytic signaling; (iv) mTORC1 hyperactivation in “mTORopathies” (e.g., DEPDC5-related focal cortical dysplasia) with aberrant neuronal growth and synaptic function; (v) epigenetic dysregulation interacting with inflammatory and synaptic pathways; and (vi) mitochondrial/oxidative stress that lowers seizure threshold and perpetuates injury–inflammation cycles. Recent human studies have mapped altered E/I and gene expression to cognitive outcomes (TLE), demonstrated BBB causal roles and druggable stabilization strategies, and advanced precision therapies including SCN1A antisense oligonucleotides (ASOs) and senolytics for mTOR-related dysmorphic neurons (2022–2024) (duma2024excitationinhibitionbalancerelates pages 1-3, han2024unveilingthehidden pages 1-2, greene2022microvascularstabilizationvia pages 1-2, yuan2024asorestoresexcitability pages 1-2, ribierre2024targetingpathologicalcells pages 1-2).

URLs: - E/I mapping in TLE (Brain Communications, 2024): https://doi.org/10.1093/braincomms/fcae231 (duma2024excitationinhibitionbalancerelates pages 1-3) - BBB and epilepsy (Frontiers in Neurology, 2024): https://doi.org/10.3389/fneur.2024.1413023 (han2024unveilingthehidden pages 1-2) - BBB stabilization prevents seizures (Nature Communications, 2022): https://doi.org/10.1038/s41467-022-29657-y (greene2022microvascularstabilizationvia pages 1-2) - SCN1A ASO in Dravet model (Brain, 2024): https://doi.org/10.1093/brain/awad349 (yuan2024asorestoresexcitability pages 1-2) - Senolytics in mTOR-related epilepsy (Nature Neuroscience, 2024): https://doi.org/10.1038/s41593-024-01634-2 (ribierre2024targetingpathologicalcells pages 1-2)

1. Core Pathophysiology

  • E/I imbalance and ion channelopathies: In TLE, noninvasive EEG aperiodic exponent mapping identified regional E/I shifts that correlate with cognitive deficits and cortical expression of GABRA1, GRIN2A, GABRD, GABRG2, KCNA2, and PDYN, directly linking E/I to molecular architecture (Brain Communications 2024) (duma2024excitationinhibitionbalancerelates pages 1-3). Genetic epilepsies involve loss-/gain-of-function in voltage-gated potassium channels (KCNA1/2, KCNB1, KCNC1, KCND2, KCNQ2/3, KCNH1/5) that alter repolarization and network excitability (Frontiers in Neurology 2024) (zheng2024voltagegatedpotassiumchannels pages 1-2).
  • Glial neuroinflammation: Reactive astrocytes and microglia, activated by DAMPs (e.g., HMGB1), propagate cytokine signaling (IL-1, IL-6, TNF) via TLR/NF-κB and related pathways; sustained inflammation feeds seizure propensity and drug resistance (IJMS 2024) (sanz2024neuroinflammationandepilepsy pages 1-2).
  • BBB dysfunction and albumin–TGF-β–astrocyte signaling: Reviews and translational studies converge that BBB breakdown increases permeability, leads to albumin uptake by astrocytes, weakens junctions, perturbs ionic homeostasis, and contributes to epileptogenesis; BBB changes also limit drug penetration (Frontiers in Neurology 2024) (han2024unveilingthehidden pages 1-2). Human surgical tissue and mouse models show claudin-5 loss, albumin/IgG extravasation, and neuroinflammation; claudin-5 knockdown induces spontaneous seizures, whereas RepSox restores claudin-5 and prevents seizures (Nature Communications 2022) (greene2022microvascularstabilizationvia pages 1-2).
  • mTOR/DEPDC5 and cortical malformations: Brain somatic mosaicism of mTORC1 pathway genes (MTOR, RHEB) or loss of repressors (DEPDC5/GATOR1, TSC1, PTEN) in cortical progenitors causes focal malformations (FCD/HME), shared pyramidal neuron morphological and excitability abnormalities, and gene-specific synaptic changes (eLife 2024) (nguyen2024themtorpathway pages 1-2). DEPDC5 loss hyperactivates mTORC1; rapamycin rescues biochemical and survival phenotypes in Depdc5 neuronal KO mice (HMG 2019) (yuskaitis2019chronicmtorc1inhibition pages 2-3).
  • Epigenetic regulation: Epileptogenesis involves epigenetic dysregulation affecting inflammatory and synaptic genes; antiepileptogenic strategies targeting epigenetic and inflammatory processes are under study (Health Science Reports 2024) (shariff2024advancesinunderstanding pages 5-6, shariff2024advancesinunderstanding pages 4-5).
  • Mitochondrial/oxidative stress: Oxidative stress and mitochondrial dysfunction (e.g., ROS, mtDNA injury) contribute to neuronal hyperexcitability and amplify inflammatory cascades, reinforcing epileptogenesis (Health Science Reports 2024) (shariff2024advancesinunderstanding pages 5-6).

2. Key Molecular Players

  • Genes/Proteins (HGNC):
  • SCN1A (Nav1.1): GABAergic interneuron haploinsufficiency → impaired inhibition (ASO upregulates Scn1a; restores PV-IN sodium currents and GABA signaling) (yuan2024asorestoresexcitability pages 1-2).
  • GABRA1/GABRG2: GABA-A receptor subunits; human E/I mapping correlates with cortical expression; mutations reduce inhibitory currents (duma2024excitationinhibitionbalancerelates pages 1-3).
  • KCNQ2/KCNQ3 (Kv7.2/7.3): M-current reduction drives neonatal DEEs; channelopathies underpin hyperexcitability (zheng2024voltagegatedpotassiumchannels pages 1-2).
  • KCNA2 and other Kv genes: diverse LOF/GOF epilepsies shaping excitability (zheng2024voltagegatedpotassiumchannels pages 1-2).
  • DEPDC5 (GATOR1): mTORC1 disinhibition → cortical malformations and focal epilepsy (nguyen2024themtorpathway pages 1-2, yuskaitis2019chronicmtorc1inhibition pages 2-3).
  • MTOR/RHEB/PTEN/TSC1: mTORC1 axis; mutations drive “mTORopathies” (nguyen2024themtorpathway pages 1-2).
  • CLDN5 (claudin-5): endothelial tight junction; loss associates with BBB leakage and seizures (greene2022microvascularstabilizationvia pages 1-2).

  • HMGB1/TLR4: DAMP–TLR signaling in neuroinflammation (sanz2024neuroinflammationandepilepsy pages 1-2).

  • Chemical Entities (ChEBI):

  • γ-aminobutyric acid (GABA; CHEBI:16865); L-glutamate (CHEBI:29988) – neurotransmitters of inhibitory/excitatory balance (duma2024excitationinhibitionbalancerelates pages 1-3).
  • Albumin (CHEBI:16580) – extravasated BBB cargo activating astrocytic TGF-β signaling (han2024unveilingthehidden pages 1-2).
  • Everolimus/rapamycin (mTOR inhibitors; CHEBI:68478, CHEBI:9168) – mTORopathy-directed therapies (yuskaitis2019chronicmtorc1inhibition pages 2-3, nguyen2024themtorpathway pages 1-2).
  • Dasatinib (CHEBI:467849) + Quercetin (CHEBI:16243) – senolytic regimen reducing seizures in mTOR-FCD model (ribierre2024targetingpathologicalcells pages 1-2).
  • Cannabidiol (CHEBI:69478) – precision adjunct with syndrome-specific benefit (context of precision care) (li2025progressingenetic pages 3-4).

  • RepSox (ALK5/TGF-β signaling modulator) – BBB stabilization and seizure prevention in mice (greene2022microvascularstabilizationvia pages 1-2).

  • Cell Types (CL):

  • Parvalbumin-positive (PV) GABAergic interneurons – selectively impaired in SCN1A; ASO restores function (yuan2024asorestoresexcitability pages 1-2).
  • Excitatory cortical pyramidal neurons – altered morphology/excitability in mTORopathy models (nguyen2024themtorpathway pages 1-2).
  • Astrocytes – albumin uptake, TGF-β signaling; glutamate/GABA homeostasis; inflammatory mediators (han2024unveilingthehidden pages 1-2, sanz2024neuroinflammationandepilepsy pages 1-2).
  • Microglia – innate immune activation (TLR/NLR), cytokine release; network effects (sanz2024neuroinflammationandepilepsy pages 1-2).

  • Endothelial cells/pericytes – BBB structural components (han2024unveilingthehidden pages 1-2).

  • Anatomical Locations (UBERON):

  • Hippocampus (temporal lobe) – human TLE focus, BBB disruption (greene2022microvascularstabilizationvia pages 1-2).
  • Neocortex (focal cortical dysplasia) – mTOR-related malformations and epileptogenic nodes (nguyen2024themtorpathway pages 1-2).
  • Cerebral microvasculature – BBB (han2024unveilingthehidden pages 1-2).

3. Biological Processes (GO terms; disrupted in epilepsy)

  • Synaptic transmission, GABAergic (GO:0051932); inhibitory postsynaptic potential (GABA-A complex) (duma2024excitationinhibitionbalancerelates pages 1-3).
  • Synaptic transmission, glutamatergic (GO:0035249) and regulation of postsynaptic membrane potential (duma2024excitationinhibitionbalancerelates pages 1-3).
  • Regulation of membrane potential/action potential (GO:0042391; GO:0001508) via Na+ and K+ channels (zheng2024voltagegatedpotassiumchannels pages 1-2, yuan2024asorestoresexcitability pages 1-2).
  • Blood–brain barrier establishment/maintenance (GO:1903160) and endothelial cell–cell adhesion (greene2022microvascularstabilizationvia pages 1-2, han2024unveilingthehidden pages 1-2).
  • mTORC1 signaling (GO:0031931), regulation of translation and cell growth (nguyen2024themtorpathway pages 1-2, yuskaitis2019chronicmtorc1inhibition pages 2-3).
  • Innate immune response, TLR signaling (GO:0002224), NF-κB signaling, cytokine production (sanz2024neuroinflammationandepilepsy pages 1-2).
  • Response to oxidative stress/ROS and mitochondrial processes (GO:0006979) (shariff2024advancesinunderstanding pages 5-6).

4. Cellular Components (GO)

  • Axon initial segment; voltage-gated sodium/potassium channel complexes (yuan2024asorestoresexcitability pages 1-2, zheng2024voltagegatedpotassiumchannels pages 1-2).
  • GABA-A receptor complex; postsynaptic density (duma2024excitationinhibitionbalancerelates pages 1-3).
  • Tight junction (endothelial) at BBB (greene2022microvascularstabilizationvia pages 1-2).
  • Lysosomal surface/cytosol (mTORC1 localization and regulation) (nguyen2024themtorpathway pages 1-2).
  • Extracellular space (HMGB1 as DAMP upon release) (sanz2024neuroinflammationandepilepsy pages 1-2).

5. Disease Progression (sequence of events)

  • Initiation: genetic predisposition (e.g., ion channel or mTOR pathway variants) or acquired injury (TBI, infection) → acute seizures, BBB opening, and DAMP release (han2024unveilingthehidden pages 1-2, nguyen2024themtorpathway pages 1-2, shariff2024advancesinunderstanding pages 4-5).
  • Latency/epileptogenesis: BBB leakage (albumin/IgG), astrocytic TGF-β signaling, microglial activation, cytokine cascades, oxidative stress, and synaptic/network remodeling (han2024unveilingthehidden pages 1-2, greene2022microvascularstabilizationvia pages 1-2, sanz2024neuroinflammationandepilepsy pages 1-2, shariff2024advancesinunderstanding pages 5-6).
  • Chronic epilepsy: stabilized network hyperexcitability with E/I imbalance (regional), persistent neuroinflammation, structural lesions (FCD/HME) in mTORopathies; cognitive comorbidity correlates with E/I maps (duma2024excitationinhibitionbalancerelates pages 1-3, nguyen2024themtorpathway pages 1-2).

6. Phenotypic Manifestations (HPO) and links to mechanisms

  • Seizures (HP:0001250) and status epilepticus (HP:0002133): emergent property of E/I imbalance, BBB dysfunction, and inflammatory signaling (han2024unveilingthehidden pages 1-2, greene2022microvascularstabilizationvia pages 1-2, sanz2024neuroinflammationandepilepsy pages 1-2).
  • Cognitive impairment (HP:0100543), memory deficits (HP:0002354): correlate with E/I changes in entorhinal/dorsolateral prefrontal cortices in TLE (duma2024excitationinhibitionbalancerelates pages 1-3).
  • Developmental delay (HP:0001263) and epileptic encephalopathy (HP:0200134): channelopathies (SCN1A, KCNQ2/3) and mTORopathies (DEPDC5/TSC1) (yuan2024asorestoresexcitability pages 1-2, zheng2024voltagegatedpotassiumchannels pages 1-2, nguyen2024themtorpathway pages 1-2).

Key evidence items with PMIDs/DOIs, URLs, dates (quotes where available)

  • E/I mapping in human TLE: “EEG aperiodic exponent maps the E/I balance non-invasively... correlation between the exponent and the cortical expression of GABRA1, GRIN2A, GABRD, GABRG2, KCNA2 and PDYN” (Brain Communications, 2024-02-23; https://doi.org/10.1093/braincomms/fcae231) (duma2024excitationinhibitionbalancerelates pages 1-3).
  • Kv channelopathies: “Both gain and loss-of-function of Kv channels lead to epilepsy with similar phenotypes through different mechanisms” (Frontiers in Neurology, 2024-10-14; https://doi.org/10.3389/fneur.2024.1466075) (zheng2024voltagegatedpotassiumchannels pages 1-2).
  • Neuroinflammation cascade: “DAMPs such as HMGB1… activate PRRs (TLRs, NLRs) → NF-κB… reactive glia release cytokines/ROS” (IJMS, 2024-04-09; https://doi.org/10.3390/ijms25084161) (sanz2024neuroinflammationandepilepsy pages 1-2).
  • BBB roles and mechanisms: “Disruption of the blood–brain barrier… increased leakage… albumin is taken up into astrocytes” (Frontiers in Neurology, 2024-08-21; https://doi.org/10.3389/fneur.2024.1413023) (han2024unveilingthehidden pages 1-2).
  • BBB stabilization as therapy: “Claudin-5 levels are diminished in TLE; inducible knockdown leads to spontaneous seizures… RepSox… can prevent seizure activity” (Nature Communications, 2022-04-13; https://doi.org/10.1038/s41467-022-29657-y) (greene2022microvascularstabilizationvia pages 1-2).
  • mTOR/DEPDC5 mechanisms: “Somatic mutations in mTORC1 genes… produce shared alterations… but different changes in excitatory synaptic transmission” (eLife, 2024-02-23; https://doi.org/10.7554/eLife.91010.3) (nguyen2024themtorpathway pages 1-2). “mTORC1 inhibitor rapamycin… prolonged survival of Depdc5cc+ mice and rescued downstream mTORC1 hyperactivity” (HMG, 2019-05-24; https://doi.org/10.1093/hmg/ddz123) (yuskaitis2019chronicmtorc1inhibition pages 2-3).
  • Senolytics for FCD/mTOR: “Dysmorphic neurons exhibit senescence signatures… dasatinib/quercetin decreased senescent cells and reduced seizure frequency” (Nature Neuroscience, 2024-05-27; https://doi.org/10.1038/s41593-024-01634-2) (ribierre2024targetingpathologicalcells pages 1-2).
  • SCN1A ASO precision therapy: “ASO-84 restored action potential firing, sodium current density, and GABAergic signaling in PV+ interneurons” (Brain, 2024-10-01; https://doi.org/10.1093/brain/awad349) (yuan2024asorestoresexcitability pages 1-2).

Current applications and real-world implementations

  • Precision neuromodulation of E/I: EEG aperiodic exponent can noninvasively map E/I and relate to cognition and cortical gene expression, suggesting utility for stratification and monitoring in TLE (duma2024excitationinhibitionbalancerelates pages 1-3).
  • BBB-directed interventions: Imaging/evidence of BBB disruption in human refractory epilepsy; preclinical evidence supports targeting tight junctions (claudin-5 upregulation with RepSox) as a seizure-preventive strategy (greene2022microvascularstabilizationvia pages 1-2, han2024unveilingthehidden pages 1-2).
  • mTOR-targeted therapy: Rapamycin/everolimus are clinically used in TSC and supported as rational strategies for DEPDC5-related epilepsies by preclinical mechanistic rescue (yuskaitis2019chronicmtorc1inhibition pages 2-3, nguyen2024themtorpathway pages 1-2).
  • Senotherapy: Early preclinical evidence for senolytics (dasatinib/quercetin) reducing seizures in mTOR-related FCD models (ribierre2024targetingpathologicalcells pages 1-2).
  • Gene-directed therapy: SCN1A ASO (poison exon skipping) restores PV interneuron function in Dravet mice; serves as mechanistic basis for clinical translation (yuan2024asorestoresexcitability pages 1-2).

Expert perspectives (authoritative sources)

  • E/I imbalance in humans is quantifiable and genetically anchored in cortex, linking physiology to gene expression and cognition (Brain Communications 2024) (duma2024excitationinhibitionbalancerelates pages 1-3).
  • The BBB is not merely a bystander but a mechanistic contributor and drug resistance modulator; claudin-5 represents a tractable target (Nature Communications 2022; Frontiers in Neurology 2024) (greene2022microvascularstabilizationvia pages 1-2, han2024unveilingthehidden pages 1-2).
  • mTORopathies converge on mTORC1 hyperactivation but diverge in synaptic transmission, implying gene-specific precision strategies beyond “class-wide” mTOR inhibition (eLife 2024) (nguyen2024themtorpathway pages 1-2).
  • Reactive gliosis and innate immune sensors (HMGB1–TLR) are central to epileptogenesis; anti-inflammatory/immune-modulatory approaches remain promising adjuncts (IJMS 2024) (sanz2024neuroinflammationandepilepsy pages 1-2).

Relevant statistics and data

  • TLE patients displayed significantly larger EEG aperiodic exponent values (inhibition-directed E/I), with regional exponents correlating with worse verbal memory (quantitative correlation) and with expression of GABRA1, GRIN2A, GABRD, GABRG2, KCNA2, PDYN (duma2024excitationinhibitionbalancerelates pages 1-3).
  • Human TLE resections show significantly reduced claudin-5 protein and widespread BBB leakage by DCE-MRI; inducible claudin-5 knockdown in mice induces spontaneous recurrent seizures (greene2022microvascularstabilizationvia pages 1-2).
  • In human FCDII slices, epileptiform activity correlated with dysmorphic neuron density (e.g., ≈54 vs 12 DNs/mm² between hyperactive vs quieter areas); senolytics reduced seizure frequency in MtorS2215F mice (ribierre2024targetingpathologicalcells pages 1-2).

Gene/protein annotations with ontology terms (selected)

HGNC symbol Full name Primary mechanism in epilepsy (1–2 lines) Pathway(s) GO Biological Process (examples) GO Cellular Component (examples) Key cell types (CL names) Key anatomy (UBERON names) Anchor citations
SCN1A Sodium voltage-gated channel alpha subunit 1 Haploinsufficiency/LOF in GABAergic interneurons → reduced inhibition, network hyperexcitability Voltage-gated sodium channel / action potential generation Regulation of membrane potential; action potential; sodium ion transmembrane transport Axon initial segment; plasma membrane; voltage-gated sodium channel complex GABAergic interneurons (parvalbumin-positive, somatostatin-positive) Cerebral cortex; hippocampus (yuan2024asorestoresexcitability pages 1-2, zhang2025dravetsyndromenovel pages 15-16)
GABRA1 GABA A receptor alpha1 subunit LOF/reduced surface expression → impaired inhibitory synaptic currents and reduced GABAergic tone GABAergic synaptic transmission Inhibitory synaptic transmission; chloride transport; synaptic transmission Postsynaptic membrane; GABA-A receptor complex; synapse Pyramidal neuron postsynaptic sites; interneuron synapses Cortex; hippocampus (duma2024excitationinhibitionbalancerelates pages 1-3, sanz2024neuroinflammationandepilepsy pages 1-2)
GABRG2 GABA A receptor gamma2 subunit Mutations impair receptor biogenesis/clustering → decreased synaptic inhibition and DEE phenotypes GABA-A receptor assembly and synaptic localization Inhibitory synaptic transmission; receptor trafficking Postsynaptic density; plasma membrane; GABA-A receptor complex GABAergic synapses; interneuron→pyramidal neuron synapses Cortex; hippocampus (duma2024excitationinhibitionbalancerelates pages 1-3, sanz2024neuroinflammationandepilepsy pages 1-2)
KCNQ2 Potassium voltage-gated channel subfamily Q member 2 (Kv7.2) Loss-of-function reduces M-current → neonatal hyperexcitability, developmental impairment Kv7 (M-current) / neuronal excitability control Potassium ion transmembrane transport; regulation of neuronal excitability Plasma membrane; axon initial segment; potassium channel complex Excitatory neurons; developing cortical neurons Cortex; hippocampus (zheng2024voltagegatedpotassiumchannels pages 1-2, liu2024excitatoryneuronsand pages 1-3)
KCNQ3 Potassium voltage-gated channel subfamily Q member 3 (Kv7.3) Partners with KCNQ2 in M-current; variants modulate channel function and excitability Kv7 (M-current) / heteromeric KCNQ2/3 channels Regulation of membrane potential; potassium ion transport Plasma membrane; axon initial segment Excitatory neurons; developing neurons Cortex; hippocampus (zheng2024voltagegatedpotassiumchannels pages 1-2, liu2024excitatoryneuronsand pages 1-3)
KCNA2 Potassium voltage-gated channel subfamily A member 2 (Kv1.2) Kv channel dysfunction (LOF/GOF) alters repolarization → network hyperexcitability or aberrant firing Kv1 family / action potential repolarization Potassium ion transmembrane transport; regulation of action potential Plasma membrane; presynaptic terminal; ion channel complex Excitatory neurons; inhibitory interneurons Cortex; hippocampus (duma2024excitationinhibitionbalancerelates pages 1-3, zheng2024voltagegatedpotassiumchannels pages 1-2)
DEPDC5 DEP domain containing 5 (GATOR1 complex subunit) LOF → loss of GATOR1 repression → mTORC1 hyperactivation; somatic/germline variants cause FCD and focal epilepsy GATOR1 → mTORC1 regulation Regulation of mTOR signaling; cell growth; autophagy regulation Cytosol; lysosomal membrane (mTORC1 localization) Excitatory neuronal progenitors / cortical neurons Focal cortex (cortical malformations, FCD) (yuskaitis2019chronicmtorc1inhibition pages 2-3, nguyen2024themtorpathway pages 1-2, ribierre2024targetingpathologicalcells pages 1-2)
MTOR Mechanistic target of rapamycin kinase mTORC1 hyperactivation → abnormal neuronal growth/plasticity, epileptogenesis in mTORopathies mTORC1 signaling / protein synthesis and growth Regulation of translation; cell growth; synaptic plasticity Cytosol; lysosomal membrane; mTORC1 complex Neurons (excitatory), progenitors, glia Cortex (FCD), hippocampus (nguyen2024themtorpathway pages 1-2, yuskaitis2019chronicmtorc1inhibition pages 2-3)
RHEB Ras homolog enriched in brain Small GTPase activator of mTORC1; gain-of-function → mTORC1 activation in cortical development mTORC1 activation via Rheb-GTP Positive regulation of mTOR signaling; regulation of cell growth Cytosol; lysosomal membrane Neuronal progenitors; excitatory neurons Cortex; developing telencephalon (nguyen2024themtorpathway pages 1-2)
PTEN Phosphatase and tensin homolog Loss reduces PI3K/AKT inhibition → increased mTOR signaling and altered neuronal morphology/excitability PI3K-AKT- mTOR pathway regulation Negative regulation of PI3K signaling; cell growth control Cytosol; plasma membrane; nucleus Neurons; glia; progenitors Cortex; hippocampus (nguyen2024themtorpathway pages 1-2)
TSC1 Tuberous sclerosis 1 Part of TSC1/TSC2 complex suppressing mTORC1; loss → mTORC1-driven cortical dysplasia and seizures TSC complex → mTORC1 inhibition Negative regulation of mTOR signaling; cell growth; autophagy Cytosol; lysosomal membrane Neuronal progenitors; neurons Cortex (tuberous sclerosis lesions), hippocampus (yuskaitis2019chronicmtorc1inhibition pages 2-3, nguyen2024themtorpathway pages 1-2)
CLDN5 Claudin-5 Tight junction protein; decreased expression → BBB leakage, albumin extravasation and seizure susceptibility Tight junction / BBB integrity Establishment of blood–brain barrier; cell–cell adhesion Tight junction; endothelial cell membrane Brain endothelial cells; pericytes; astrocyte end-feet Cerebral microvasculature; hippocampus (greene2022microvascularstabilizationvia pages 1-2)
HMGB1 High mobility group box 1 Damage-associated molecular pattern (DAMP) released after injury/seizures → activates innate immunity and promotes epileptogenesis DAMP signaling → TLR/NF-κB / inflammasome activation Release of DAMPs; positive regulation of inflammatory response; cytokine production Nucleus (normal); extracellular space (released DAMP) Microglia; astrocytes; neurons Hippocampus; cortex (sanz2024neuroinflammationandepilepsy pages 1-2)
TLR4 Toll-like receptor 4 Pattern recognition receptor sensing HMGB1/LPS → NF-κB activation, cytokine release, neuroinflammation linked to seizure propagation TLR signaling → NF-κB / inflammasome pathways Innate immune response; cytokine-mediated signaling; inflammatory response Plasma membrane; endosome (signaling) Microglia; astrocytes; endothelial cells Hippocampus; cortex (sanz2024neuroinflammationandepilepsy pages 1-2)

Table: Concise ontology-ready table mapping 14 epilepsy-relevant genes/proteins to mechanisms, pathways, GO processes/components, cell types, anatomical sites and anchor citations; useful for knowledgebase annotations and GO/ontology curation.

Phenotype associations (HPO), Cell types (CL), Anatomy (UBERON), Chemicals (ChEBI)

  • HPO: HP:0001250 Seizure; HP:0002133 Status epilepticus; HP:0100543 Cognitive impairment; HP:0002354 Memory impairment (duma2024excitationinhibitionbalancerelates pages 1-3, han2024unveilingthehidden pages 1-2, greene2022microvascularstabilizationvia pages 1-2).
  • CL: PV GABAergic interneuron; astrocyte; microglial cell; brain endothelial cell; pericyte (yuan2024asorestoresexcitability pages 1-2, sanz2024neuroinflammationandepilepsy pages 1-2, han2024unveilingthehidden pages 1-2).
  • UBERON: hippocampus; cerebral cortex (temporal neocortex); cerebral microvasculature (greene2022microvascularstabilizationvia pages 1-2, nguyen2024themtorpathway pages 1-2, han2024unveilingthehidden pages 1-2).
  • ChEBI: GABA (CHEBI:16865), L-glutamate (CHEBI:29988), albumin (CHEBI:16580), rapamycin/sirolimus (CHEBI:9168), everolimus (CHEBI:68478), dasatinib (CHEBI:467849), quercetin (CHEBI:16243), cannabidiol (CHEBI:69478) (han2024unveilingthehidden pages 1-2, greene2022microvascularstabilizationvia pages 1-2, ribierre2024targetingpathologicalcells pages 1-2, yuan2024asorestoresexcitability pages 1-2, yuskaitis2019chronicmtorc1inhibition pages 2-3, nguyen2024themtorpathway pages 1-2, li2025progressingenetic pages 3-4).

Single-cell/spatial transcriptomics in human epilepsy

  • Multimodal single-nucleus RNA/ATAC profiling of human FCD IIIa temporal neocortex revealed selective dysregulation of excitatory neurons (including a DAB1high subpopulation with immune signatures) and activated OPCs, with aberrant EN–OPC communication validated by protein assays (Clinical and Translational Medicine, 2024-10-15; https://doi.org/10.1002/ctm2.70072) (liu2024excitatoryneuronsand pages 1-3).

Precision therapeutics—summary of opportunities

  • SCN1A ASOs (poison-exon modulation) restore PV interneuron excitability, sodium current density, and GABAergic drive in Dravet mice; supports translation to mechanism-guided trials (yuan2024asorestoresexcitability pages 1-2).
  • mTOR inhibition (rapamycin/everolimus) rational in TSC and mechanistically supported for DEPDC5-related epilepsies; gene-specific differences suggest combining with synapse-focused strategies (yuskaitis2019chronicmtorc1inhibition pages 2-3, nguyen2024themtorpathway pages 1-2).
  • BBB stabilization (targeting claudin-5/TGF-β signaling modulators such as RepSox) prevents seizures in models; motivates biomarker-driven patient selection in DRE with BBB leakage (greene2022microvascularstabilizationvia pages 1-2, han2024unveilingthehidden pages 1-2).
  • Senolytics (dasatinib/quercetin) reduce seizure burden in mTOR-FCD models by ablating senescent dysmorphic neurons; a candidate disease-modifying approach needing careful safety evaluation (ribierre2024targetingpathologicalcells pages 1-2).

Evidence list (citable items)

  • Duma et al., Brain Communications, 2024-02-23. URL: https://doi.org/10.1093/braincomms/fcae231 (duma2024excitationinhibitionbalancerelates pages 1-3).
  • Han et al., Frontiers in Neurology, 2024-08-21. URL: https://doi.org/10.3389/fneur.2024.1413023 (han2024unveilingthehidden pages 1-2).
  • Greene et al., Nature Communications, 2022-04-13. URL: https://doi.org/10.1038/s41467-022-29657-y (greene2022microvascularstabilizationvia pages 1-2).
  • Zheng & Chen, Frontiers in Neurology, 2024-10-14. URL: https://doi.org/10.3389/fneur.2024.1466075 (zheng2024voltagegatedpotassiumchannels pages 1-2).
  • Sanz et al., IJMS, 2024-04-09. URL: https://doi.org/10.3390/ijms25084161 (sanz2024neuroinflammationandepilepsy pages 1-2).
  • Nguyen et al., eLife, 2024-02-23. URL: https://doi.org/10.7554/eLife.91010.3 (nguyen2024themtorpathway pages 1-2).
  • Yuskaitis et al., Human Molecular Genetics, 2019-05-24. URL: https://doi.org/10.1093/hmg/ddz123 (yuskaitis2019chronicmtorc1inhibition pages 2-3).
  • Ribierre et al., Nature Neuroscience, 2024-05-27. URL: https://doi.org/10.1038/s41593-024-01634-2 (ribierre2024targetingpathologicalcells pages 1-2).
  • Yuan et al., Brain, 2024-10-01. URL: https://doi.org/10.1093/brain/awad349 (yuan2024asorestoresexcitability pages 1-2).
  • Liu et al., Clinical and Translational Medicine, 2024-10-15. URL: https://doi.org/10.1002/ctm2.70072 (liu2024excitatoryneuronsand pages 1-3).
  • Shariff et al., Health Science Reports, 2024-02. URL: https://doi.org/10.1002/hsr2.1896 (shariff2024advancesinunderstanding pages 5-6, shariff2024advancesinunderstanding pages 4-5).

References

  1. (duma2024excitationinhibitionbalancerelates pages 1-3): Gian Marco Duma, Simone Cuozzo, Luc Wilson, Alberto Danieli, Paolo Bonanni, and Giovanni Pellegrino. Excitation/inhibition balance relates to cognitive function and gene expression in temporal lobe epilepsy: a high density eeg assessment with aperiodic exponent. Brain Communications, Feb 2024. URL: https://doi.org/10.1093/braincomms/fcae231, doi:10.1093/braincomms/fcae231. This article has 25 citations and is from a peer-reviewed journal.

  2. (han2024unveilingthehidden pages 1-2): Jinkun Han, Ying Wang, Penghu Wei, Di Lu, and Yongzhi Shan. Unveiling the hidden connection: the blood-brain barrier’s role in epilepsy. Frontiers in Neurology, Aug 2024. URL: https://doi.org/10.3389/fneur.2024.1413023, doi:10.3389/fneur.2024.1413023. This article has 6 citations and is from a peer-reviewed journal.

  3. (greene2022microvascularstabilizationvia pages 1-2): Chris Greene, Nicole Hanley, Cristina R. Reschke, Avril Reddy, Maarja A. Mäe, Ruairi Connolly, Claire Behan, Eoin O’Keeffe, Isobel Bolger, Natalie Hudson, Conor Delaney, Michael A. Farrell, Donncha F. O’Brien, Jane Cryan, Francesca M. Brett, Alan Beausang, Christer Betsholtz, David C. Henshall, Colin P. Doherty, and Matthew Campbell. Microvascular stabilization via blood-brain barrier regulation prevents seizure activity. Nature Communications, Apr 2022. URL: https://doi.org/10.1038/s41467-022-29657-y, doi:10.1038/s41467-022-29657-y. This article has 145 citations and is from a highest quality peer-reviewed journal.

  4. (yuan2024asorestoresexcitability pages 1-2): Yukun Yuan, Luis Lopez-Santiago, Nicholas Denomme, Chunling Chen, Heather A O'Malley, Samantha L Hodges, Sophina Ji, Zhou Han, Anne Christiansen, and Lori L Isom. Aso restores excitability, gaba signalling and sodium current density in a model of dravet syndrome. Brain : a journal of neurology, 147:1231-1246, Oct 2024. URL: https://doi.org/10.1093/brain/awad349, doi:10.1093/brain/awad349. This article has 36 citations.

  5. (ribierre2024targetingpathologicalcells pages 1-2): Théo Ribierre, Alexandre Bacq, Florian Donneger, Marion Doladilhe, Marina Maletic, Delphine Roussel, Isabelle Le Roux, Francine Chassoux, Bertrand Devaux, Homa Adle-Biassette, Sarah Ferrand-Sorbets, Georg Dorfmüller, Mathilde Chipaux, Sara Baldassari, Jean-Christophe Poncer, and Stéphanie Baulac. Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mtor-related epilepsy. Nature Neuroscience, 27:1125-1136, May 2024. URL: https://doi.org/10.1038/s41593-024-01634-2, doi:10.1038/s41593-024-01634-2. This article has 35 citations and is from a highest quality peer-reviewed journal.

  6. (zheng2024voltagegatedpotassiumchannels pages 1-2): Yiting Zheng and Jing Chen. Voltage-gated potassium channels and genetic epilepsy. Frontiers in Neurology, Oct 2024. URL: https://doi.org/10.3389/fneur.2024.1466075, doi:10.3389/fneur.2024.1466075. This article has 22 citations and is from a peer-reviewed journal.

  7. (sanz2024neuroinflammationandepilepsy pages 1-2): Pascual Sanz, Teresa Rubio, and Maria Adelaida Garcia-Gimeno. Neuroinflammation and epilepsy: from pathophysiology to therapies based on repurposing drugs. International Journal of Molecular Sciences, 25:4161, Apr 2024. URL: https://doi.org/10.3390/ijms25084161, doi:10.3390/ijms25084161. This article has 62 citations and is from a poor quality or predatory journal.

  8. (nguyen2024themtorpathway pages 1-2): Lena H Nguyen, Youfen Xu, Maanasi Nair, and Angelique Bordey. The mtor pathway genes mtor, rheb, depdc5, pten, and tsc1 have convergent and divergent impacts on cortical neuron development and function. eLife, Feb 2024. URL: https://doi.org/10.7554/elife.91010.3, doi:10.7554/elife.91010.3. This article has 33 citations and is from a domain leading peer-reviewed journal.

  9. (yuskaitis2019chronicmtorc1inhibition pages 2-3): Christopher J Yuskaitis, Leigh-Ana Rossitto, Sarika Gurnani, Elizabeth Bainbridge, Annapurna Poduri, and Mustafa Sahin. Chronic mtorc1 inhibition rescues behavioral and biochemical deficits resulting from neuronal depdc5 loss in mice. Human molecular genetics, 28:2952-2964, May 2019. URL: https://doi.org/10.1093/hmg/ddz123, doi:10.1093/hmg/ddz123. This article has 58 citations and is from a domain leading peer-reviewed journal.

  10. (shariff2024advancesinunderstanding pages 5-6): Sanobar Shariff, Halah A. Nouh, Samuel Inshutiyimana, Charbel Kachouh, Maya M. Abdelwahab, Abubakar Nazir, Magda Wojtara, and Olivier Uwishema. Advances in understanding the pathogenesis of epilepsy: unraveling the molecular mechanisms: a cross‐sectional study. Health Science Reports, Feb 2024. URL: https://doi.org/10.1002/hsr2.1896, doi:10.1002/hsr2.1896. This article has 21 citations and is from a peer-reviewed journal.

  11. (shariff2024advancesinunderstanding pages 4-5): Sanobar Shariff, Halah A. Nouh, Samuel Inshutiyimana, Charbel Kachouh, Maya M. Abdelwahab, Abubakar Nazir, Magda Wojtara, and Olivier Uwishema. Advances in understanding the pathogenesis of epilepsy: unraveling the molecular mechanisms: a cross‐sectional study. Health Science Reports, Feb 2024. URL: https://doi.org/10.1002/hsr2.1896, doi:10.1002/hsr2.1896. This article has 21 citations and is from a peer-reviewed journal.

  12. (li2025progressingenetic pages 3-4): Yang Li, Xiaojie Hu, Xueqing Chen, Yawei Cheng, Yanhong Jiang, and Xingchen Wang. Progress in genetic mechanisms and precise treatment of neurocutaneous syndrome-related epilepsy. Frontiers in Neurology, Sep 2025. URL: https://doi.org/10.3389/fneur.2025.1642299, doi:10.3389/fneur.2025.1642299. This article has 0 citations and is from a peer-reviewed journal.

  13. (zhang2025dravetsyndromenovel pages 15-16): Guirui Zhang, Shupeng Huang, Mingzhen Wei, Yongmo Wu, Zhengyi Xie, and Jin Wang. Dravet syndrome: novel insights into scn1a-mediated epileptic neurodevelopmental disorders within the molecular diagnostic-therapeutic framework. Frontiers in Neuroscience, Jul 2025. URL: https://doi.org/10.3389/fnins.2025.1634718, doi:10.3389/fnins.2025.1634718. This article has 3 citations and is from a peer-reviewed journal.

  14. (liu2024excitatoryneuronsand pages 1-3): Yingying Liu, Yinchao Li, Yaqian Zhang, Yubao Fang, Lei Lei, Jiabin Yu, Hongping Tan, Lisen Sui, Qiang Guo, and Liemin Zhou. Excitatory neurons and oligodendrocyte precursor cells are vulnerable to focal cortical dysplasia type iiia as suggested by single‐nucleus multiomics. Clinical and Translational Medicine, Oct 2024. URL: https://doi.org/10.1002/ctm2.70072, doi:10.1002/ctm2.70072. This article has 3 citations and is from a peer-reviewed journal.